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Inflammatory bowel disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBD). Complex 
environmental, immunoregulatory, and genetic factors interact in this pathologic process, resulting 
in chronic, relapsing intestinal inflammation. UC is characterized by a diffuse mucosal 
inflammation limited to the colon. It involves the rectum in nearly all cases and may extend 
proximally to the rest of the large intestine. The most specific clinical symptom is bloody diarrhea. 
CD is characterized by a more discontinuous inflammatory pattern, potentially affecting the whole 
gastrointestinal tract. The inflammation in CD is transmural with large ulcerations and occasional 
granuloma. Symptoms of CD are abdominal pain and diarrhea, but patients may also suffer from 
rectal bleeding, weight loss, and fever. Worldwide, up to two million people suffer from IBD (1-4).  
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Both UC and CD are mainly located in areas with high bacterial concentrations. There is evidence 
that IBD is caused by a (genetically determined) altered immune response to antigens of the enteric 
bacterial microbiota in a genetically susceptible host (5-8). In this hypothesis the gut microbiota, 
host defense, and genetics of the host are inextricably linked and can be displayed by a vicious 
circle, where the one process, inflammatory response, may lead to the other process, a change in 
microbiota composition or activity, or vice versa (Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Possible interaction and cause- and effect- relations between inflammatory reactions and 
intestinal microbiota in IBD. 
The role of the microbiota in IBD 
Interactions between the intestinal microbiota and the host have been suggested to play a role in the 
pathogenesis of CD and UC. First of all, the distal ileum and the colon are the areas of the gut with 
the highest bacterial concentrations and are the more frequent sites of inflammation in IBD patients 
as well (9). Furthermore, decreasing bacterial numbers in the intestine, e.g. by using antibiotics, can 
lead to clinical improvement and decreased inflammation in both humans (10) and animal models 
of IBD (11,12). Diversion of the faecal stream was studied in patients after curative resection of the 
distal ileum. A diverting terminal ileostomy was constructed. These patients only had a recurrence 
of disease after reanastomosis, but not during the six months in which the neoterminal ileum and 
colon were excluded from intestinal transit (13). This finding further points to the involvement of 
the microbiota in the etiology of mucosal inflammation in IBD. 
A large variety of observations, often using transgenic animals, support the hypothesis that IBD is 
due to T cell hyper responsiveness towards otherwise harmless components of the indigenous 
microbiota (14). HLA-B27/ß-microglobulin transgenic rats and IL-10 knock-out mice, develop IBD 
in the presence of a normal colonic microbiota, but not under germfree conditions (11,15,16).  
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Moreover, CD4+ T cells (T-helper cells) reactive towards antigens of the enteric bacteria produce 
colitis after adoptive transfer to immunodeficient hosts (17). It is not so much the presence of a 
specific microorganism, but the immune response to it that appears critical in the pathogenesis of 
IBD.  
Circumstantial evidence for the role of the microbiota in IBD includes responses to antimicrobial 
therapy, infiltration of inflammatory bacterial products across the intestinal mucosal barrier, host 
immunity against (or rather loss of tolerance to) bacteria indigenous to the large intestine, and the 
role of bacteria in disease development in animal models of IBD. Currently, two hypotheses 
regarding the role of microorganisms in IBD are under investigation. The first suggests that specific 
microorganisms play a role in the induction of inflammation (2,18-21). The second suggests that 
metabolites derived from the microbiota, without regard to species, can be mediators of injury and 
inflammation (22,23) hereby driving a perpetuous circle as depicted in Figure 1.1.  
Composition of the microbiota 
A wide spectrum of organisms, including Escherichia coli, Bacteroides vulgatus, Clostridium 
difficile, Campylobacter jejuni, Mycobacterium paratuberculosis, Salmonella typhimurium, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa, is thought to be linked to IBD (7,19,24). If 
specific microorganisms cause mucosal inflammation, the composition of the microbiota from IBD 
patients may be different from that of healthy individuals. Various investigators compared the 
microbiota of IBD patients to that of healthy individuals, but results on this are conflicting (5,7,25).  
However, in severe, extensive IBD an abnormal composition of the gut microbiota may be a result, 
rather than a cause, of the disease. For instance, diarrhea can lead to secondary, non-specific 
increases in faecal aerobes and coli forms and thus in a reduced number of anaerobic bacteria and 
lactobacilli. This is a common feature in active colitis, regardless of the cause (6). Not only a 
pathological symptom such as diarrhea, but also the treatment of IBD patients with antimicrobials 
or other drugs can result in a microbiota that is different in composition from that of healthy 
individuals (5,25).  
Also, most data have been obtained using classical plating and speciation techniques. These 
observations are limited by the fact that only approximately 40% of the microbiota can be 
cultivated. By taking more modern molecular approaches, such as Denaturing Gradient Gel 
Electrophoresis (DGGE), fluorescent in situ hybridization (FISH), or DNA-arrays (DNA-chips), 
one may come to well-founded conclusions about microbial compositions, which are more specific 
and non-conflicting. 
Metabolic activity of the microbiota 
The second hypothesis explaining the role of the microbiota in IBD focuses on its metabolic 
activity. Published data suggest that the metabolic activity of the large intestinal microbiota of 
patients suffering from UC and CD is different compared to that of healthy individuals (7,23,26-
28). This difference in activity, as evidenced by the production of certain microbial metabolites, 
may be a mediator of mucosal injury. 
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The metabolic activity of the colonic microbiota is an anaerobic fermentation process in which 
substrates are metabolized by the large intestinal microbiota to salvage energy (29). This process is 
influenced by the composition of the colonic microbiota as well as by the amount and type of 
substrate that enters the colon, consisting of dietary residues (mainly carbohydrates and proteins) 
and host-produced substances (e.g. mucin, sloughed-off epithelial cells) (3,22,29,30).  
The presence of carbohydrates influences proteolytic fermentation, and vice versa. (2,22,31). 
Protein fermentation, in particular, gives rise to a variety of metabolites that are potentially toxic, 
including phenolic and indolic compounds, branched-chain fatty acids (BCFA), sulphur-containing 
metabolites, and ammonia. In absolute amounts the turnover of nitrogenous substances is less than 
that of carbohydrates and organic acids (29,32). However, little is known about the production and 
biological role in vivo of these potentially toxic metabolites derived from proteolytic fermentation. 
The within-subject variation turned out to be high when faeces was used to determine 
concentrations of phenolic and indolic compounds, BCFA, and ammonia (30). Studies focusing on 
these metabolites in different regions of the colon showed that the proteolytic activity of gut 
bacteria is higher in the distal parts of the large intestine, where pH is increasing amongst others 
because of decreased carbohydrate fermentation (2,22,31). The protein fermentative metabolites 
have been associated with a variety of disease states in humans, including cancer. They seem to 
have several cytopathic effects on colonic epithelial cells, for intstance reduction of their lifespan 
(2). Protein fermentation potentially plays a role in IBD by causing damage to epithelial cells in 
genetically susceptible hosts, thereby resulting in inflammatory reactions. 
Besides a high proteolytic activity, a low saccharolytic activity can possibly also influence the 
pathogenesis of IBD. Bacterially-produced short-chain fatty acids (SCFA), especially butyrate, are 
important energy sources for colonic epithelial cells; the colonocytes acquire approximately 70% of 
their energy from butyrate (33). Depletion of butyrate or prevention of the oxidative use of butyrate 
by epithelial cells leads to loss of integrity of these cells and, eventually, results in death and 
epithelial desquamation (34) (35-38). This is presumably the case in UC (35,39). Renewal of the 
lost cells increases proliferation and may eventually influence the chance of cancer development 
(40). In addition, the increased desquamation due to a lack of SCFA leads to a decreased barrier 
function of the gut wall and makes the colonic epithelium more susceptible to bacterial 
translocation and inflammation (Figure 1.1)(25). In some initial studies, enemas containing SCFA 
decreased disease activity in left-sided colitis. Additional studies are needed to evaluate this 
therapy. Presently, no link has been found between CD and SCFA. Both the reduction in butyrate or 
other health promoting metabolites and the increase in toxic compounds seem to influence the 
health status of the epithelial layer lining the colon.  
Also the elevation of other bacterial enzymatic activities can contribute to the clinical picture. 
Patients with active UC have higher mucin sulfatase activity than those with inactive UC.  
Furthermore Rafii et al. (6) found significantly higher total glycosidase activity in fecal samples of 
patients with CD than in healthy subjects. Both sulfatase and glycosidase have been implicated in 
the impairment of the protective function of the mucus barrier. Other enzymes, such as 
azoreductase, nitroreductase, oxidoreductase, and glucuronidase activities can potentially lead tot 
toxic metabolites (6,41).  
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Role of nutrition in IBD 
A high prevalence of nutritional disturbances and deficiencies occur in IBD. Nutritional therapies 
can be used in control of the disease activity in CD. Elemental diets, which are mainly used in 
enteral nutrition therapy, seem to reduce mucosal inflammations by the elimination of dietary 
antigens and by reductions in fat. Parenteral nutrition is utilized as complete bowel rest supporting 
nutrition (42). 
In this thesis another role of nutrition in IBD is discussed, based on the knowledge that the 
microbial activity in the colon may play a role in IBD. This activity is in part defined by the 
components of the food that reach this part of the digestive tract. Especially the nutritional approach 
in UC is evident, focusing on the metabolic activity in the colon (43,44). Instead of elimination of 
dietary compounds and establishing bowel rest, dietary compounds can be added to the normal diet 
to control disease activity. These dietary compounds are called prebiotics, defined as nondigestible 
food ingredients that beneficially affect the host by selectively stimulating the growth or activity of 
one or a limited number of bacterial species already resident in the colon (45). Lactulose, 
oligofructose, inulin, bran, psyllium, and germinated barley all have been proposed as prebiotics 
(46-49). Fermentation of prebiotics can for instance result in high amounts of butyrate and they are 
able to manipulate the microbiota towards a more remedial community (10,50). Also, prebiotics 
often exhibit waterholding capacity and bile-acid binding capacity. This high water-holding 
capacity results in a positive effect on stool formation. Furthermore, such prebiotics seem to be 
more readily utilized by microorganisms. A high capacity for binding bile-acids results in a higher 
excretion of these compounds, which are a causal factor in colorectal cancer (48,51). However, 
more detailed studies are needed to clearly establish the relevance of prebiotics in IBD. A short-
term synbiotic therapy, in which Bifidobacterium longum was combined with inulin, resulted in 
improvement of the clinical appearance of chronic inflammation in patients with active UC (52). 
Defense 
An intact gastrointestinal mucosa, with a normal intestinal permeability and barrier function, is 
essential for fluid-absorption and -secretion and transport of oxygen, ions, and nutrients. Intestinal 
epithelial cells that line the gastrointestinal mucosa can be regarded as the most outer defense 
system preventing microorganisms, including commensals, and endotoxins from reaching systemic 
organs and tissues (34,53-57). 
It has been suggested that both luminal microorganisms and their metabolites, as well as dietary 
antigens, are capable of initiating and sustaining intestinal mucosal inflammation. An intriguing 
hypothesis regarding the pathogenesis of CD speculates that a defect in epithelial barrier function 
initiates the disease (58-60). By studying IL-10 deficient mice, Madsen et al. (1999) found that 
increased intestinal permeability existed prior to the development of mucosal inflammation, 
indicating that increased intestinal permeability is thus not secondary to mucosal inflammation (61).  
When the mucosal barrier function is impaired, bacterial translocation may increase as a result of 
paracellular- or transcellular migration. Paracellular migration involves the opening up of tight 
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junctions and subsequent penetration of the bacteria between the enterocytes; in transcellular 
migration bacteria adhere to the cells, are taken up by endocytosis, and transported within vesicles 
to the basolateral membrane (62). Besides bacteria, also microbial metabolites can be transported. 
Both can be regarded as biological active substances that may activate or influence the mucosal 
immune system leading to an inflammatory reaction (17,25,55,61,63,64).  
Failure to terminate or down regulate an immune response results in persistent and chronic 
inflammation. Many chronic inflammatory disorders show a pattern of relapse and remission. This 
is best explained by variation in exposure of immunocompetent cells to the antigenic stimulus, but 
may also reflect phased changes in immune responsiveness caused by nonspecific ‘priming’ of the 
immune system, as may occur with exposure to antigenically unrelated microorganisms (7). 
Finally, the failure to prohibit or down regulate an immune response can be the result of inherited 
predisposition. Among the candidate genes for IBD investigated to date, only the NOD2/CARD15 
gene on chromosome 16 has been definitively associated with CD (65) (66). Nucleotide-binding 
oligomerisation domain (NOD) molecules detect, together with Toll-like receptors (TLR), 
microbial ligands in order to initiate a defense response to fight infectious disease. These microbial 
ligands are structural components of the microorganism that are not subject to much variation, like 
lipopolysaccharide (LPS) and peptidoglycan from the cell walls of bacteria. NOD2/CARD15 act as 
an activator of nuclear factor (NF)-КB and is thus involved in innate immunity (65,67-69). Variants 
of proteins critically involved in bacterial antigen recognition, such as the products of CD-
associated NOD2/CARD15 mutations seem to contribute to the loss of tolerance to commensal 
bacteria in CD (66). Currently, the NOD2-dependent signaling cascade is poorly understood (70). 
Gut Immunology in IBD 
Irrespective of whether or not the primary disorder in IBD is immunological in nature, the immune 
system is heavily involved in the inflammatory processes that cause this condition. In the healthy 
intestine, immune systems are self-tolerant and controlled by powerful, self-regulating mechanisms. 
But when IBD ensues, the inflammatory processes turn into confounding factors that camouflage 
what could otherwise be an explicit inflammatory response.  
Mucosal B cells 
Activated B cells are called plasma cells. They produce immunoglobulins (Ig), of which there are 
five classes (IgA, IgG, IgM, IgD and IgE), which bind to invading organisms, eventually leading to 
their destruction. The IBD-involved intestine shows a massive increase in the number of plasma 
cells and this increase is not uniform; IgA, IgM, and IgG producing cells increasing 2-, 5-, and 30-
fold, respectively (71,72). Furthermore, the two forms of IBD can be distinguished based on IgG 
subclass: IgG1 increasing more in UC and IgG2 in CD. The reason for this difference is unclear, but 
distinct immune regulatory mechanisms or genetically conditioned differences may be responsible 
(73,74) (25). Alternatively, the same antigens driving the disease into a TH-1 (CD) or a TH-2 (UC) 
response (see below) can also cause the difference in production of IgG subclass. 
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Mucosal T cells 
T-helper (TH) cells are the T cell type that is involved in IBD. TH cells produce cytokines and 
chemokines and are classified in TH-1 cells and TH-2 cells. A TH-1 response results in an early 
increase in the expression of interleukin (IL)-2, interferon (INF)-γ, and IL-12, followed by a 
subsequent increase in tumour necrosis factor (TNF)-α and IL-18, and a compensatory increase in 
IL-10 and tumour growth factor (TGF)-β. TH-1 cells mediate cellular immunity and macrophage 
activation. TH-2 cells mediate humoral immunity and produce IL-4, IL-5, IL-6, IL-10 and IL-13. 
Production of IFN-γ inhibits differentiation of TH-2 cells, and IL-10 can diminish TH-1 responses 
(9,75). This latter depends on the local concentrations achieved; high systemic doses seem to be 
correlated with an immunostimulatory effect of IL-10 (76). 
The dysbalance between the humoral and cell-mediated immune responses may play an important 
role in the pathogenesis of UC and CD. The two major IBD diseases may be different in their 
etiology as evidenced by the fact that the immunological respons of both CD and UC is of opposite 
nature. An increase in TH-1 cytokines is detected in CD patients, whereas in patients affected by 
UC, TH-2 cell activation was demonstrated (25,59,77,78). 
Macrophages 
Also nonspecific cellular immunity is altered in IBD. In active IBD lesions a large number of blood 
monocytes can be detected, probably because of an increased demand of macrophages in the 
inflamed gut (79). This macrophage population is very heterogeneous and they are evident in early 
IBD lesions (25,80) Intestinal activated macrophages are distinct in phenotype and function from 
blood monocytes: they retain phagocytic and bacteriocidal activity. Furthermore, they do not 
produce proinflammatory cytokines, except small amounts of IL-8, upon stimulation by an array of 
proinflammatory agents (e.g. LPS) (81). Whether intestinal activated macrophages in IBD patients 
behave like intestinal activated macrophages in healthy individuals is poorly understood. 
Surface bounderies and -excretions  
The structure of both the small and large intestine is made up of four layers: mucosa, submucosa, 
muscularis, and serosa. The mucosal epithelium consists of a heterogenous population of cells that 
change in morphology with progression from the crypt base to the villus (82). There are four major 
intestinal cell types: simple columnar cells (almost 90% of the villus population), large numbers of 
mucus-secreted goblet cells, enteroendocrine cells and Paneth cells (at the base of the crypt). 
Lymphatic nodules are present in the mucosa, and the larger aggregates of lymphatic tissue are 
known as Peyer’s patches (83). 
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Figure 1.2 Colonic mucosa. DC=dendritic cells; MS=mesenchymal cells; MP=macrophages; HLA class 
II=human leucocyte antigen class II; TLR=Toll Like Receptor; LPS=lipopolysacharide. 
The gut mucosa plays a central role in the exclusion and elimination of potentially harmful antigens 
and microorganisms, while providing selective absorption (Figure 1.2). Antigen exclusion has been 
associated with factors such as the capacity of the gut mucosa to produce secretory IgA and mucus. 
Secretory IgA seems to prevent the adherence of enteral antigens to the mucosal surface, and mucus 
protects against microbial infestation (84).  
Epithelial cells 
Intestinal immunity consists of a functional integration of local immune cells with cells of 
nonimmune origin. Among these nonimmune cells, epithelial cells have been studied the most 
extensively. Epithelial cells are one of many kinds of cells that form the epithelium and they absorb 
nutrients. Their reciprocal interaction with the adjacent immune cells is well recognized. Human 
enterocytes and colonocytes express human leukocyte antigen (HLA) class II proteins and can 
function as antigen-presenting cells (APC), with CD4+ TH cells responding to the antigens 
displayed on their surfaces (85). Furthermore, the epithelial cells play an important role in the 
prevention of TLR activation by commensal microorganisms. This family of receptor molecules, of 
which some are expressed on the epithelial cells, function as sensors of microbial infection and 
initiate immune defense responses. A normal epithelial surface prevents the translocation of 
commensals. However, pathogenic bacteria that are translocated can subsequently be detected by 
the TLR that are expressed on macrophages and dendritic cells (86,87). 
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Evidence of epithelial cell involvement in IBD is derived from various studies. Epithelial cells 
respond to IL-1, IL-2, IL-15, and TNF-α and secrete IL-7, which activates lamina propria 
mononuclear cells. Furthermore, epithelial cells can produce IL-8 and TNF-α; and they express 
leukocyte adhesion molecules (25,56,88). Abnormalities of epithelial cell phenotype and function 
are found in IBD, of which a defective capacity to induce CD8+ T-supressor cells (TS) is potentially 
important. Whereas normal epithelial cells preferentially activate TS cells, a function that might 
contribute to induction of local tolerance, IBD epithelial cells preferentially activate CD4+ TH cells, 
perhaps leading to an amplification of local immune reactivity and inflammation. Finally, there is 
the intriguing suggestion that the colonic epithelium in UC fails to adequately oxidize butyrate. The 
result can be an energy-deficient condition of the mucosa, and thus the gut barrier function may be 
impaired (35,89). Irrigation of diversion colitis with SCFA and use of butyrate enemas in distal UC 
result in marked clinical improvements (25,90). 
Endothelial cells 
The microvascular endothelial cell is another important nonimmune cell that regulates mucosal 
homeostasis. Recruitment of activated leucocytes, one of the most important functions of innate 
immunity, is mediated by cell-adhesion molecules that are induced on the surface of endothelial 
cells. First, the P- or E-selectins initiate endothelial-leucocyte interactions by binding to fucosylated 
oligosaccharide ligands on passing leucocytes. The next step depends on a tighter adhesion, which 
is due to intercellular adhesion molecules (ICAMs) on the endothelium binding to heterodimer 
proteins of the integrin family on leucocytes. MadCAM-1 is an intercellular adhesion molecule that 
is specific for the gut epithelium. P- and E-selectins, ICAMs, and MadCAM-1 are expressed on the 
surface of endothelial cells following production of TNF-α by macrophages, and the adhesive 
properties of integrins like LFA-1 and MAC-1 on leucocytes are increased in response to IL-8 or 
other chemokines (85). 
Markers of prothrombotic state and endothelial lesion and physiologic inhibitors of coagulation in 
plasma support the hypothesis that IBD patients harbor endothelial lesions with sustained 
coagulation activation. This endothelial damage is probably secondary to intestinal injury (25,91). 
Furthermore, the features of endothelial cells seem to be altered in IBD. Isolated intestinal mucosal 
endothelial cells of IBD patients show a markedly enhanced capacity to bind leukocytes compared 
with cells from normal mucosa. This enhanced binding by IBD endothelial cells persists regardless 
of in vitro culture time, suggesting that persistence of inflammation may also result from a 
hyperadhesive intestinal microvasculature. Similar functional modifications may very well occur 
for other cell types, ultimately creating a self-perpetuating proinflammatory loop sustained by the 
activity of nonimmune cells, a mechanism also underlying other types of chronic inflammation 
(17,25). Biological therapies against adhesion molecules that are being used in clinical practice at 
present or investigated for the treatment of IBD are anti-ICAM-1 and the anti-α-4 integrin 
antibodies natalizumab (Antegren®) and LDP-02 (92-94). 
General introduction 
17 
Colonic mucus 
The mucosal epithelial cells are protected from mechanical injury, the action of antigens and toxins, 
and the invasion of enteric bacteria by a layer of mucus. Mucus is secreted by goblet cells; the main 
constituent is a glycoprotein (mucin) that contains up to 85% carbohydrates. Common constituents 
of the carbohydrate are fucose, galactose, N-acetyl (Nac)-glucosamine, NAc-neuraminic acid, and 
mannose in an α- or β-glycoside linkage. Mucus serves as an important energy source for the 
bacterial microbiota in the intestine, and it acts as a lubricant to ease the passage of stool through 
the colon (2,95-97). 
A breakdown of the mucus barrier will increase the exposure of the epithelium to the full impact of 
luminal aggressors and may thereby contribute to the pathophysiology of IBD (25,98). Mucus 
thickness was significanlty reduced and the layer became discontinuous in active UC (98). Bacterial 
enzymes, such as glycosidases and sulfatases, together with host-derived proteases, have been 
implicated in the impairment of the protective function of the mucus barrier. Together they are 
responsible for the degradation of the glycoproteins (6,99,100). There is experimental evidence that 
colonic mucin-glycoconjugates are altered in UC due to bacterial glycosidases, which are able to 
release monosaccharides from the polysaccharide chains that surround the protein core of the 
glycoprotein (6). However, studies on mucin composition in UC patients are conflicting. But even if 
colonic mucin alterations would be present, they alone would probably be insufficient to trigger 
inflammation (25). 
Microbiota 
Early exposure at the neonatal stage of the gut mucosa to live microorganisms and bacterial 
colonization, together with the introduction of dietary antigens, play an important role in the 
development of gut barrier functions and unresponsiveness to ingested antigens (oral tolerance). 
The microbiota enhances the development of the barrier by increasing the population of IgA-
plasmocytes and the number of enteroendocrine cells in the jejunal and colonic epithelium, 
enhancing the production of secretory IgA and mucus. The microbiota have also been shown to 
stimulate proliferation of epithelial cells and increase the total intestinal surface. Demonstration that 
the intestinal microbiota constitutes an important part of the exclusive components of the mucosal 
barrier has led to the introduction of novel modes of therapeutic intervention, using specific strains 
of microorganisms as probiotics (84). 
Treatment of IBD 
Medical therapy for IBD 
Treatment of IBD varies according to the type, distribution and severity of disease. Although 
surgery is indicated in certain situations, drug therapy is the approach of choice to induce remission 
and then prevent relapse. Currently no medical or surgical cure exists for CD, for UC cure can be 
obtained by proctocolectomy, but such extensive surgery is usually only offered when drug therapy 
has failed or when dysplasia occurs. Thus the goals of medical treatment are generally restricted to 
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suppress the inflammatory response, to relieve symptoms and to induce disease remission. Drugs in 
the treatment of IBD can be used topically, orally or intravenously. Commonly used drugs include 
aminosalicylates, corticosteroids, antibiotics, and immunomodulatory agents (8,101). 
Aminosalicylates  
Sulfasalazine consists of the active component mesalazine (5-aminosalicylic acid; 5-ASA) and 
sulfapyridine joined by an azo-bond. Sulfasalazine remains inactive in the proximal gastrointestinal 
tract, but in the colon bacterial cleavage of the azo-bond occurs, making 5-ASA available only to 
the large intestinal mucosa. There are a number of drugs that contain only 5-ASA, consisting of a 
single molecule (Pentasa®, Asacol®, Salofalk® and Claversal®/Mesasal®) or 2 molecules joined by 
an azo-bond (Dipentum®). Various mechanisms to deliver the active drug to its site of action are 
used; most often the disintegration of the formula is based on pH. Aminosalicylates are used in the 
treatment of mild to moderately active UC and mildly active CD, and for maintenance of remission 
(101-103). 
Corticosteroids 
Corticosteroids block the production and effects of cytokines and additional inflammatory 
mediators, and therefore have effects on many cellular and humoral immune functions. Examples of 
steroids in the treatment of IBD are prednisolone, budesonide (Entocort®, Budenofalk®), 
beclomethasone dipropionate, and fluticasone propionate. Corticosteroids are proven efficaceous in 
acute UC and CD, but not as maintenance therapy because of lack of effect and their association 
with side effects (101,104,105). Especially budesonide is of scientific and clinical interest because 
of its topical delivery. Therefore, budesonide is less likely to cause serious side effects compared to 
other corticosteroids (105). 
Antibiotics 
Antibiotics have been used by clinicians for many years. They can selectively decrease tissue 
invasion by microorganisms and eliminate aggressive bacterial species or globally decrease luminal 
and mucosal bacterial concentrations, depending on their spectrum of activity. Examples used in 
both active CD and UC are clarithromycin, ciproflaxin, metronidazole, vancomycin, and imipenem. 
They sometimes are also used to maintain remission but then appear to have a less significant 
impact on clinical course and parameters of inflammatory activity in patients with UC 
(10,12,101,106,107). 
Immunomodulatory agents 
Azathioprine (AZA), its active metabolite 6-mercaptopurine (6-MP), methotrexate (MTX), and 
cyclosporine are the four primary immunomodulatory agents used in IBD patients. These drugs 
alter the immune response via inhibition of T-cell mediated responses, natural killer cell activity, or 
cytokine production. These immunosuppressants are valuable drugs for those forms of IBD that are 
unresponsive to other forms of treatment. Azathioprine and 6-MP are mainly used for maintenance 
therapy in both UC and CD. Methotrexate is also used for maintenance therapy in CD. 
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Cyclosporine is only used in active UC (8,101). Newer immunomodulatory agents that are 
emerging are mentioned in the next paragraph.  
Biological therapy for IBD 
Novel therapeutic approaches for the treatment of IBD are currently emerging. These often use 
biologic agents that mechanistically target individual inflammatory pathways. Biological agents that 
have already been proven to be effective for CD and recently for UC include monoclonal antibodies 
directed against tumour necrosis factor alpha (anti-TNF-α; infliximab and CDP571) and to the 
leukocyte adhesion molecule α-4 integrin (natalizumab)(92,93,108). Still under investigation are 
among others interferon-α, anti interleukin-12 (IL-12) antibody, human growth hormone, IL-10, IL-
11, and antisense-oligonucleotides which either block the genetic read out of adhesion molecule 
genes such as ICAM-1 or of the intracellular regulatory factor NF-қB (77,101,106,109).  
Besides immunological strategies, also the targeting of therapeutics to improve topical delivery is a 
strategy for IBD that can be realized using a biological approach (105,106). In microbiological 
strategies, microorganisms are used to modify the gut microbiota. The used microorganisms are 
called probiotics. Probiotics are defined as living organisms, which beneficially affect the host. The 
probiotic organisms influence the diverse functions of the colonic microbiota, which contains more 
than 500 different bacterial species. It is thought that probiotic organisms can correct any imbalance 
between the beneficial and harmful activities. Probiotics could also increase the defense of the body 
against pathogens through immunomodulatory activities (110,111). More recently also genetically 
engineered bacteria can function as probiotic, such as lactococci that secrete immunosuppressive 
IL-10 (10). 
Studying microbiota in IBD 
Faeces 
Faeces can be used to study the role of specific microorganisms in the induction of IBD. Molecular 
approaches have recently shown that the microbial composition of faeces is comparable to the 
microbial composition of the luminal contents in the proximal colon, as well as that of the colonic 
mucosa (112). Zoetendal et al. (113), on the other hand, used a 16S rRNA approach to demonstrate 
that the predominant mucosa associated bacterial community was significantly different from the 
faecal community. But the community of Lactobacillus-like bacteria in biopsy samples was similar 
to that in feaces for 6 out of 10 individuals.  
Faeces does not seem a good indicator of the fermentative activity that occurs in the proximal colon 
(114). For IBD patients, investigating faecal material is even more complex. Damage to the mucosa 
of IBD patients, caused by inflammation, can result in inadequate absorption and utilization of 
metabolites and therefore may result in higher concentrations of metabolites in their faeces than in 
that of healthy individuals (7). With faeces, no distinction can be made between an inadequate 
absorption and utilization and an actual altered metabolic functioning by luminal bacteria from IBD 
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patients. This latter can be studied in an in vitro model of the proximal colon, using faeces as 
inoculum. 
In vitro model of the large intestine (TIM-2) 
To study microbial activity, a dynamic model of the large intestine was developed by TNO (115). 
The model (nick-named TIM-2 for TNO’s in vitro model of the large intestine) consists of a 
number of linked glass units with flexible walls inside (Figure 1.3). Peristaltic movements are 
achieved by pumping water of body temperature (37°C) into the space between the glass jacket and 
the flexible wall at regular intervals. The computer controls the sequential squeezing of the walls, 
causing the chyme to be mixed and moved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model is equipped with hollow fibre membranes, inside the lumen of the model, to remove 
water and microbial fermentation products, such as SCFA. Thereby, they maintain the physiological 
concentrations of small molecules, such as electrolytes, and prevent product inhibition (and 
eventually microbial death) due to built-up of microbial metabolites (46,116). The model further 
contains an inlet system for delivery of the artificial ileal delivery medium. The system is kept 
anaerobic by flushing with gaseous nitrogen, to allow for the growth of a dense, complex 
microbiota, comparable in composition and activity to that found in humans in the proximal colon 
(117).
Figure 1.3  
Dynamic in vitro model  
of the large intestine (TIM-2). 
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Cell cultures 
Absorption and local and systemic biotransformation of microbial metabolites, as well as tolerance 
to microbes and microbial metabolites of epithelial cells can be assessed using in vitro and ex vivo 
approaches. These assays are especially suitable for screening of microorganisms or microbial 
metabolites separately and in certain combinations. It has been suggested that both luminal 
microorganisms and their metabolites are capable of initiating and sustaining intestinal mucosal 
damage and/or inflammation by negatively affecting defense systems. Among others, the following 
two cell cultures have been be used to study this hypothesis.  
Caco-2  
The human colon carcinoma cell line Caco-2 has been widely used as an in vitro model for human 
intestinal absorption as these cells display, after differentiation, both biochemical and 
morphological characteristics of intestinal enterocytes (118,119). Differentiation of Caco-2 cells can 
proceed along multiple pathways and does not necessarily lead to apoptosis. The phenotypic 
changes during spontaneous differentiation (17-21 days) mimic those that occur in normal colonic 
epithelial cells in vivo during their migration from the crypt base to the neck. A butyrate-induced 
differentiation (2-3 days) more closely follows that occurring when normal colonic epithelial cells 
migrate from the crypt neck to the surface compartment (120). 
In this thesis, Caco-2 cells grown on semi-permeable inserts in a two-compartment transport system 
(Figure 1.4) were used to study the effect of microbial metabolites on the barrier function. The 
permeability characteristics of compounds across Caco-2 monolayers were found to correlate well 
with in vivo absorption data in humans after an oral intake (121,122). We also used the model to 
study immunologic effects of microbial compounds.  
 
 
 
 
Figure 1.4  
Monolayer of Caco-2 cells grown on semi-
permeable inserts in a two-compartment cell 
culture system (SEM). 
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Macrophages 
During a local infection or inflammation, the affected tissue is rapidly infiltrated by large numbers 
of exudate (inflammatory) macrophages. These inflammatory macrophages have distinct 
characteristics compared to the resident macrophages that are normally present in various organs 
(123). Several cell lines are available that are widely used as model systems for monocytes and 
macrophages. The human monocytic cell line U937, used in this thesis, is a tumor cell line that 
originates from immature cells of the monocytic differentiation lineage corresponding to 
monoblasts (124).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By stimulating the cells with phorbol 12-myristate 13-acetate (PMA), one of the most potent tumor 
promoting agents (125), cells are induced to undergo monocytic differentiation. In this way the cells 
acquire the typical monocyte/macrophage morphology, become adhesive, express differentiation 
related antigens and are no longer able to proliferate. Furthermore, the cells become functionally 
similar to monocyte/macrophage-like cells that can perform phagocytosis, cytokine production, 
antibody dependent cellular cytotoxicity, antigen presentation and chemotaxis (Figure 1.5)(126).  
Figure 1.5  
 
 
Macrophage with projectile-looking surface is 
interacting with lymphocytes which are rounded. 
 
 
 
 
 
 
 
A macrophage extends a semiliquid projection, a 
so-called pseudopodium, towards some bacteria in 
the foreground. 
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Aim and outline of this thesis 
The experiments described in this thesis envisaged determining whether patients with IBD show 
evidence of an altered metabolic activity of the gut microbiota and whether this is related to the 
initiation or exacerbation of the disease. The TNO dynamic in vitro models of the upper 
gastrointestinal tract and the large intestine, and defense systems such as Caco-2 and macrophage 
cultures can be used to study the mechanisms that underlie the onset, or the progression, of UC and 
CD. The provided biomarkers can possibly be used in prevention and treatment of the disease in 
humans. 
In chapter 2 we studied which metabolites are produced during the normal colonic 
fermentation process by a healthy microbiota and which metabolites are produced if this 
microbiota is out-of-balance. TNO's dynamic in vitro model of the large intestine (TIM-2) was 
used to investigate the production of microbial metabolites by a standardized microbiota, 
representative for the healthy human proximal colon. The effect of (potential) prebiotics on 
saccharolytic- and proteolytic activity of the colonic microbiota was investigated. The emphasis 
was on toxic metbolites, such as ammonia, phenols and indoles, and branched chain fatty acids. The 
proteolytic pathogen Clostridium difficile, prevalent after broad-spectrum antibiotic treatment, was 
introduced into TIM-2 to study the potential for toxic metabolite production by a microbiota that is 
out-of-balance.  
In the third chapter we studied whether IBD patients show an altered metabolic activity of the 
microbiota in the proximal colon. It is unknown whether patients with IBD have an altered 
metabolic function of the intestinal microbiota and whether this is related to the severity of the 
disease. This study described experiments using TIM-2 inoculated with fresh faeces of 6 healthy 
individuals and 8 IBD patients. Metabolites from both saccharolytic- and proteolytic fermentation 
were analyzed to determine whether patients with IBD show evidence of an altered metabolic 
activity of the microbiota in the proximal colon. 
The production of microbial metabolites may play a role in IBD by affecting the gut barrier 
function. An increase in gut permeability may subsequently trigger the intestinal immune system, 
leading to unwanted inflammatory reactions. The effects of metabolites produced in the in vitro 
colon model, TIM-2, on epithelial and immunocompetent cells could give important insight into the 
mechanisms that underlie the onset of IBD. In chapter 4, we aimed to investigate this by 
studying which metabolites, and in which concentrations, can cause injury to epithelial cells 
and subsequently stimulate unwanted immune reactions.  
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Human interleukin-10 (hIL-10) can be used in the treatment of CD since it diminishes TH-1 
responses. A new development is the targeted delivery of hIL-10 to the site of inflammation by 
bacteria. For this therapy to be efficacious, an important criterion is the survival of these 
microorganisms in the gastrointestinal tract of the host. In chapter 5 we aimed to determine 
whether targeted delivery of hIL-10 producing L. lactis could be obtained by incorporating 
the strain in an enteric-coated capsule formulation. The effect of the formulation on survival and 
metabolic activity of the recombinant L. lactis was studied in the TNO in vitro model of the 
stomach and small intestine (TIM-1), which simulates to a high degree the successive dynamic 
conditions in the upper gastrointestinal tract. 
Anti-TNF-α monoclonal antibodies block TNF-α, a powerful immune stimulator. A single 
intravenous dose of this biological therapy results in reduced CD activity scores and increased 
remission. In chapter 6 we aimed to investigate whether anti-TNF-α monoclonal antibody 
therapy for Crohn’s disease has an effect on the faecal microbiota. Microbial composition of 
faecal samples of four CD patients before and after anti-TNF-α monoclonal antibody treatment 
were investigated and compared with the microbial composition of faeces of IBD patients in 
remission and of healthy individuals. Concentrations of microbial metabolites in the faecal samples 
were determined as well. It was hypothesized that if the microbial composition correlates with 
clinical outcome, microbial metabolites possibly do as well. Therefore, the second aim of this study 
was to investigate the possible use of microbial metabolites as disease activity markers in IBD, 
given its relationship with the microbial composition.  
Chapter 7 concludes the thesis with a general discussion. This discussion is focussed on the role 
of microbial metabolites in IBD and is followed by a summary of the main conclusions derived 
from the research described in this thesis. 
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Abstract 
The influence of inulins with different average degree of polymerisation (ranging from 3 to 25) on 
the metabolic activity of the human colonic microbiota with or without the addition of Clostridium 
difficile was investigated in vitro. The in vitro system used was a dynamic, computer-controlled 
model that simulates the conditions of the proximal part of the large intestine with peristaltic 
mixing, water absorption and absorption of fermentation products. The addition of inulin stimulated 
the formation of the total amount of short-chain fatty acids acetate, propionate and butyrate up to 
50%, and that of lactate more than 10-fold, while the formation of ammonia and the branched chain 
fatty acids iso-butyrate and iso-valerate was suppressed. Ammonia formation was suppressed by 
about 30% and that of iso-butyrate and iso-valerate almost completely. These effects became much 
more pronounced when Clostridium difficile was present in the system. The introduction of 
Clostridium difficile caused a stimulation of the production of the protein fermentative metabolites 
ammonia, branched chain fatty acids and of the phenolic compounds indole, phenol and p-cresol. 
This stimulatory effect of Clostridium difficile was almost completely prevented by the addition of 
inulins. Thus, these results indicate a potential of inulins to shift the metabolic activity of the human 
colonic microbiota towards the production of less potentially toxic metabolites, both under normal 
conditions and under conditions with a disturbed microbiota (with a high level of Clostridium 
difficile). 
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Introduction 
Inulin is a reserve carbohydrate found in many plants and vegetables (1). It occurs for instance in 
wheat, onions, garlic and chicory. The inulin content ranges from less than 1% in banana, 1-4% in 
wheat, 1-7% in onion and leek to 15-20% in chicory (2). The carbohydrate polymer is composed of 
β-2,1-linked fructosyl moieties mostly with a terminal glucose. The number of fructosyl residues 
(degree of polymerisation, DP) extends from 3 to 250, mainly depending on the plant species.  
For about 15 years inulin is also available as an ingredient for foods. It is extracted from chicory 
roots and purified (see for instance reference 3). These types of inulin have a DP of 2–60, with an 
average ranging from 9 to 25. Short-chain inulins can be prepared enzymatically from sucrose with 
fructosyltransferases, or with an endo-inulinase from long-chain inulin (4). All types of inulin are 
used in a large variety of foodstuffs, both for their technological and nutritional benefits. The 
technological benefits include fat and sugar replacement (in combination with high intensity 
sweeteners), low caloric bulking agent, texturing and water binding agent, and filler/binder in 
tablets. Based on these properties it finds applications in, for instance, dairy products, in bread and 
other bakery products, in confectionery and ice, and in low or zero fat spreads. The nutritional 
benefits arise from the fact that inulin resists digestion in the human small intestine. Therefore it 
reaches the colon intact. In the first part of the colon, the caecum or proximal colon, it is fermented 
by the microbiota to short-chain fatty acids (SCFA; acetate, propionate and butyrate), lactate and 
gas. The absorption of the SCFA, and subsequent metabolism by the host, salvages some of the 
original energy in inulin. However, only about 1.5 kcal/g is delivered from inulin (compared to 3.9 
kcal/g from fructose) which explains the low caloric value (5).  
Consumption of inulins leads to an increase of Bifidobacterium and Lactobacillus species in the 
human faecal colonic microbiota (6,7). This is the so-called prebiotic activity of inulin: it increases 
the number and/or activity of specific microorganisms in the gastrointestinal tract presumed to be 
health promoting (8). Apparently the growth of these bacteria in the colon is stimulated by inulins 
as has also been found in vitro (9). This increase has been implicated to cause an inhibition of 
growth of pathogens, and other physiological effects both locally and systemically. Among these 
effects is the increased synthesis of vitamins, an increase in mineral absorption from the colon, a 
lowering of serum lipids, or the stimulation of immune functions (3,10).  
SCFA can be used by the cells of the body. Butyrate is considered a health-promoting metabolite, 
which functions as the major energy source for epithelial cells of the colon (11,12). Butyrate may 
play a role in the inhibition of colon carcinogenesis and in the regression of colitis (12,13). Acetate 
and propionate are used systemically in the body, especially in the liver (12). Lactate is metabolized 
by the muscle tissue (and will also be used to a large extent by the colonic microbiota). The 
branched chain fatty acids (BCFA) iso-butyrate and iso-valerate are produced by fermentation of 
the amino acids valine and leucine, respectively (14). The latter products may have a negative 
impact on health and can cause liver problems (12). Proteolytic fermentation can also lead to other 
(potentially) toxic components, such as ammonia and phenolic compounds (14). Ammonia is toxic 
to the colonic epithelium and promotes colon cancer in rats (15). In addition, ammonia is a 
(potential) liver toxin and has been implicated in the onset of neoplastic growth (14,16,17). The 
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production of phenolic compounds by intestinal bacteria has been associated with a variety of 
disease states in humans, including schizophrenia (14). While the role of phenols in cancer is 
unclear, nitrosation of dimethylamine, by nitrite, is stimulated by phenol, and the interaction of 
phenol with nitrite forms diazoquinone, which is mutagenic in the Ames test. Other potential 
(pro)carcinogens can also arise from the metabolic conversions of hepatically detoxified 
compounds that are secreted into the gastrointestinal tract by the liver via bile. For instance, 
bacterial β-glucuronidase can release carcinogens from hepatically derived glucuronic acid 
conjugates (13). Deconjugated bile acids, products of bacterial bile acid metabolism, have been 
implicated in the events that lead to colon cancer (18). Although a healthy person can handle a 
limited amount of these toxic metabolites, the balance of health promoting and toxic metabolites 
produced by the colonic microbiota is thought to be important for a healthy colon (19). In a 
disturbed microbiota, e.g. as the result of antibiotic treatment, this balance can be shifted towards 
more toxic metabolites.  
The objective of this study was to examine the effect of the addition of inulins of different DP on 
the activity of the human colonic microbiota in vitro. To introduce a disturbance of the microbiota 
we used Clostridium (C.) difficile and we investigated whether the addition of the various inulins 
was able to suppress the effects of the introduction of C. difficile. This microorganism is the 
causative agent of antibiotic associated diarrhoea (20) and pseudomembranous colitis (21), both 
known to be linked to disturbances of the colonic microbiota. Infection with C. difficile is a major 
problem in hospitals and leads to significant morbidity and mortality (21). 
Materials and Methods 
Materials 
Inulins were provided by Sensus Operations (Roosendaal, The Netherlands). Frutafit® IQ with an 
average DP of 9 (DP9-inulin; 84.9% > DP5) and Frutafit® TEX! with an average DP of 25 (DP25-
inulin; 99.6% > DP5) are chicory-based materials. Short-chain inulin with an average DP of 3 
(DP3-inulin; Actilight®; 5% = monomers, DP2; 38.5% = DP3; 46% = DP4; 7.7% = DP5; 2.1% > 
DP5), produced by enzymatic synthesis from sucrose, was obtained from Eridania Béghin-Say 
(Neuilly sur Seine, France). All chemicals used were of the highest analytical grade. 
Strains and faecal flora 
Clostridium difficile ATCC 17857, a human isolate, was used in the experiments. It was cultivated 
anaerobically in Schaedler bouillon at 37°C and added to the in vitro large intestinal model to a 
final number of 5 x 108–1 x 109 cells per experiment.  
Faecal microbiota samples were donated by 10 healthy, adult volunteers (employees of TNO 
Nutrition and Food Research; average age 27 yrs). They were non-smokers and had not used 
antibiotics or laxatives at least three months prior to the donation, nor had they used probiotic 
bacteria 3 weeks prior to donation. Faecal samples were collected into a gastight bag, in a plastic 
container containing an Anaerocult® strip to create anaerobic conditions. Within 10 minutes the 
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material was transferred into an anaerobic cabinet. For the production of a standardized, cultivated 
faecal microbiota, which was used for the in vitro experiments, a mixture was made using about 2 g 
faeces from each individual. This sample was cultivated in a 5 L fermentor at 37°C and pH 5.8. 
Using fed batch fermentation a final volume of 5 L was obtained in approximately 40 h. The 
fermentation medium was the artificial ileal delivery medium as described by Gibson et al. (22), 
with some modifications (see below). Anaerobic conditions were maintained by flushing the 
fermentor with gaseous nitrogen. Adequately sized samples were snap-frozen in liquid nitrogen 
(with glycerol 20% v/v as cryoprotective agent) and stored at – 80°C until further use. 
Experiments in the in vitro model of the proximal colon (TIM-2) 
Details of the in vitro model (TNO Intestinal Model, TIM-2, Figure 2.1) can be found in Minekus et 
al. (23) and Venema et al. (24). In short, the proximal colon model consists of four glass units with 
a flexible wall inside (peristaltic compartments). Water of body temperature (37ºC) was pumped 
into the space between the glass jacket and the flexible wall, causing the microbiota to be mixed and 
moved. The sequential squeezing of the walls, controlled by a computer, caused a peristaltic wave 
forcing the material to circulate through the loop-shaped system. Appropriate electrolyte and 
metabolite concentrations in the lumen were maintained with a dialysis system consisting of hollow 
fibres, running through the lumen of the reactor, through which dialysis liquid was pumped.  
 
 
 
 
 
The model further contained an inlet system for delivery of the artificial ileal delivery medium, and 
a level-sensor to maintain the luminal content at a set level. The system was kept anaerobic by 
flushing with gaseous nitrogen. At the start of each experiment the model was inoculated with 
approximately 30 mL of the standard, cultivated faecal microbiota. The microbiota was allowed to 
adapt to the model conditions for 16 h, after which the experiments started. 
Figure 2.1 Schematic representation of 
the large intestinal model TIM-2.  
a: peristaltic compartments containing 
fecal matter; b: pH-electrode; c: alkali 
pump; d: dialysis liquid circuit with 
hollow fibres; e: level-sensor; f: N2 gas 
inlet; g: in- or outlet valves;  
h: sampling-port; i: gas outlet; j: 'ileal 
delivery' container. 
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All experiments were performed in duplicate. Addition of the various inulins started after the 
adaptation period. The inulins were added to the standard ileal delivery medium (see below) and fed 
to the system at a rate of 10 g of inulin per day. In the experiments with C. difficile, the strain was 
introduced after the adaptation period in a single dosage of 5 x 108–1 x 109 cells. In all experiments 
the pH was maintained at 5.8 by titration with 2 M NaOH and the temperature was kept at 37°C. 
Every 24 h a 45 mL sample was removed from the model to simulate passage of material from the 
proximal part to the distal colon. 
In these luminal samples and samples of the dialysate taken at the same moment in time the 
concentrations of the various compounds as described below were determined. With these data and 
the known volume of the dialysate, the cumulative production of SCFA, BCFA, lactate, and 
ammonia in time was calculated. The presented data are the average of duplicate experiments, and 
were all within 10% of each average.  
Ileal delivery medium 
Gibson et al. (22) described a medium, which simulates the material passing the ileo-caecal valve in 
humans (ileal delivery). This medium was modified for the experiments in TIM-2 concerning the 
following components (g/L): 4.7 pectin, 4.7 xylan, 4.7 arabinogalactan, 4.7 amylopectin, 23.5 
casein (all from Sigma-Aldrich, Zwijndrecht, the Netherlands), 39.2 starch (BDH, Amsterdam, The 
Netherlands), 17 Tween 80 (Merck, Amsterdam, the Netherlands), 23.5 bactopeptone (Oxoid, 
Haarlem, the Netherlands), 0.4 bile (Oxoid). 
Dialysate 
Dialysis liquid contained (per litre): 2.5 g K2HPO4.3H2O, 4.5 g NaCl, 0.005 g FeSO4 .7H2O, 0.5 g 
MgSO4.7H2O, 0.45 g CaCl2.2H2O (all from Merck), 0.05 g bile (Oxoid), and 0.4 g cysteine.HCl 
(BDH), plus 1 mL of a vitamin mixture containing (per litre): 1 mg menadione, 2 mg D-biotin, 0.5 
mg vitamin B12, 10 mg pantothenate, 5 mg nicotinamide, 5 mg p-aminobenzoic acid, and 4 mg 
thiamine (all from Sigma-Aldrich).  
Analytical methods 
SCFA/BCFA 
Samples were centrifuged (12,000 rpm, 5 min) and a mixture of formic acid (20%), methanol, and 
2-ethyl butyric acid (internal standard, 2 mg/mL in methanol) was added to the clear supernatant. 
According to the method described by Jouany (25), a 0.5 µL sample was injected on a GC-column 
(Stabilwax-DA, length 15 m, ID 0.53 mm, film thickness 0.1 µm; Varian Chrompack, Bergen op 
Zoom, the Netherlands) in a Chrompack CP9001 gas chromatograph using an automatic sampler 
(Chrompack liquid sampler CP9050; Varian Chrompack).  
Lactate  
Samples for lactate analysis were centrifuged as described above. In the clear supernatant both L- 
and D-lactate were determined enzymatically (based on Boehringer, UV-method, Cat. No. 
1112821) by a Cobas Mira plus autoanalyzer (Roche, Almere, the Netherlands).  
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Ammonia  
Ammonia was measured with an ammonia selective electrode (Orion, Beverly, USA), after 
adjusting the sample with an ionic strength adjustor to bring the pH above 12. The high pH turned 
all NH4+ -ions into NH3. The electrode measured the released gas, and concentrations in the samples 
were determined via comparison with a series of standard solutions with known concentrations.  
Phenolic compounds 
Phenolic compound analyses were performed on a gas chromatograph (GC) according to methods 
described previously (26,27), with minor modifications. Chloroform was used for extraction of the 
phenolic compounds. After mixing well, samples were centrifuged (12,000 x g for 5 min), and the 
chloroform phase was diluted with methanol (1:10). To the diluted sample, 100 µL of the internal 
standard (p-nitrophenol, 10 mM) was added. Of the obtained mixture 0.5 µL was loaded onto a 
WCOT Fused Silica GC column (Varian Chrompack) using the automatic sampler.  
Determination of C. difficile 
All handlings were carried out in an anaerobic cabinet. Serial 10-fold dilutions were made in 
peptone/physiological saline (Oxoid) and were spread on CD agar (CM0601; Oxoid) with a  
C. difficile selective supplement (SR096; Oxoid) for enumeration of C. difficile. Plates were 
incubated anaerobically for 3 days at 37°C. The C. difficile strain used here (ATCC 17857) could be 
discriminated from other bacteria growing on CD agar due to its large colony size. 
Results 
SCFA production 
Both total SCFA production and SCFA ratios were used for the description of the metabolic activity 
of a microbiota; straight lines of SCFA production means a continuous production (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Cumulative SCFA production after the addition of DP9-inulin and in the absence (A) and 
presence of C. difficile (B). The cumulative production of acetate (◊), propionate (○), n-butyrate (∆) and of 
the sum of these (□) in time is shown. The additions (inulin and/or C. difficile) were made to the system at 16 
h. The inulins were added at a rate of 10 g/day.
0
50
100
150
200
250
300
350
16 40 64 88 112
time (h)
S
C
FA
 (m
m
ol
)
A
0
50
100
150
200
250
300
350
16 40 64 88 112
time (h)
S
C
FA
 (m
m
ol
)
B
Chapter 2 
40 
The main SCFA produced were acetate, propionate and butyrate (Figure 2.2 and Table 2.1). 
Valerate could hardly be detected in the experiments without C. difficile; under these circumstances 
the cumulative production of this compound remained below 1 mmol in 112 h. The total cumulative 
production as well as the SCFA ratios at the end of the experiments are represented in Table 2.1. 
Compared to the control experiment, the addition of inulins increased the total amount of SCFA 
produced and also the relative amount of propionate (Table 2.1). The percentage of butyrate 
decreased to about 15% with DP3-inulin. The total amount of SCFA increased with increasing 
chain length of the inulins (Table 2.1). 
Table 2.1 The effect of inulins of various DP on the total cumulative SCFA production and SCFA ratios 
after 112 h of fermentation in TIM-2, in the absence (-C) or presence (+C) of C. difficile.  
Control DP3-inulin DP9-inulin DP25-inulin  
SCFA -C +C -C +C -C +C -C +C 
Total production (mmol) 
Acetate (%) 
Propionate (%) 
Butyrate (%) 
230 
45.6 
18.7 
35.7 
210 
61.8 
0.6 
37.6
271 
51.0 
34.3 
14.7
144 
47.9 
20.8 
31.3
318 
41.2 
24.8 
34.0
244 
52.9 
13.5 
33.6 
338 
47.6 
27.0 
25.4 
250 
43.6 
13.2 
43.2
At 16 h C. difficile (single dosage) was added to the system and the addition of inulins was started at 10 
g/day. After 112 h samples were taken, analysed for SCFA content as described, and the cumulative SCFA 
production and percentage of individual SCFA at 112 h were calculated. 
The main effect of the addition of C. difficile to the model was a suppression of the propionate 
production (Table 2.1; Figure 2.2B), which also resulted in the total production of SCFA being less. 
This latter effect could be reversed by the addition of DP9- or DP25-inulin (210 mmol versus 244 
respectively 250 mmol; see Table 2.1). With DP3-inulin and C. difficile the lowest level of SCFA 
production was found (Table 2.1). Higher levels of valerate were detected under the conditions with 
C. difficile, but they remained very low compared to the other SCFA (maximally about 4 mmol in 
112 h was produced; data not shown). 
Lactate production 
Without inulins added there was almost no lactate produced, but it is clear from Table 2.2 that the 
addition of any type of inulin stimulated lactate production. The production was slightly larger with 
shorter chain length of the inulins. There was almost no difference in lactate production with or 
without the addition of C. difficile. 
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Table 2.2 The effect of inulins with various DP on the cumulative production of lactate after 112 h of 
fermentation in TIM-2 in the absence (-C) or presence (+C) of C. difficile.  
Control DP3-inulin DP9-inulin DP25-inulin  
Lactate -C +C -C +C -C +C -C +C 
Total production (mmol) 6 7 165 183 109 104 87 110
At 16 h C. difficile (single dosage) was added to the system and the addition of inulins was started at 10 
g/day.  
BCFA production 
The BCFA iso-butyrate and iso-valerate arise from deamination of valine and leucine, respectively. 
Their production by the human colonic microbiota in these experiments was enhanced following the 
addition of C. difficile (Figure 2.3B) compared to the control (Figure 2.3A): it resulted in a two-fold 
increase of iso-valerate production. Both without and with the pathogen added, the production of 
BCFA was strongly reduced by the addition of inulins (Figure 2.3C and 2.3D, respectively; only 
shown for DP9-inulin). Similar effects were observed with DP3- and DP25-inulin (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Cumulative production of iso-butyrate (◊) and iso-valerate (□) in time during control experiments 
(A), with the addition of C. difficile (B), DP9-inulin (C), or both DP9-inulin and C. difficile (D). The 
additions as described were made to the system at 16 h. DP9-inulin was added at a rate of 10 g/day. 
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Ammonia production 
As with the BCFA production, the ammonia production in the experiments without C. difficile (35 
mmol) was suppressed by the addition of inulins by about 30% after 112 h. Introduction of  
C. difficile resulted in a strong stimulation of ammonia formation (Figure 2.4). This stimulation was 
suppressed completely by the addition of DP25-inulin, as shown in Figure 2.4. The described 
effects were identical for DP3- and DP9-inulin (data not shown), indicating that the effect was 
independent of the average chain length of the fructan.  
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Phenolic compounds 
The production of phenolic compounds (indole, p-cresol and phenol; skatole could not be detected) 
was low under all conditions tested. Their presence could only be shown in the lumen samples and 
not in the dialysis fluid. Hence cumulative production could not be calculated for these components. 
After the introduction of C. difficile the concentration of indole increased from 612 to 620 µmol/L 
and only under this condition were p-cresol (143 µmol/L) and phenol (17 µmol/L) detected. In none 
of the experiments in which inulins were added, the phenolic compounds were present in detectable 
amounts (data not shown). These results indicated that the various inulins are able to diminish the 
production of these compounds.  
C. difficile content 
In all the experiments where C. difficile was added to the in vitro system, their number remained at 
the starting value (data not shown). Also the content of other microbiological groups did not change 
(data not shown). 
Figure 2.4 effect of the addition of 
DP25-inulin (□, ■) compared to 
the control (◊,♦) on the cumulative 
production of ammonia in the 
absence (open symbols) or 
presence (closed symbols) of C. 
difficile. At 16 h C. difficile was 
introduced to the system and the 
addition of DP25-inulin was 
started at a rate of 10 g/day.  
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Discussion 
The TNO in vitro model has been developed and validated using data from sudden death 
individuals (11,23). Both with respect to composition and with respect to metabolic activity, a 
faecal inoculum in the model has been shown to simulate the data from these sudden death 
individuals very well. In addition, we have performed experiments in the model using different 
microbiotas from dogs. The microbiotas were originating from the caecum and from faecal 
material. The microbiotas maintained in TIM-2 originating from either the caecum or faeces were 
shown to have the same composition and microbial activity as those of the microbiota when freshly 
obtained from the caecum, supporting the hypothesis that the microbiota in TIM-2 does develop to 
resemble that of the caecum (unpublished data). We hypothesize that this is also the case for a 
human microbiota. A human microbiota could be maintained stable in TIM-2 for up to three weeks 
on the standard pre-digested food, without changes in microbial composition or activity (23). 
In the experiments without C. difficile the addition of inulins suppressed the formation of BCFA 
(Fig. 2.3), ammonia (Fig. 2.4), and phenolic compounds (data not shown) while at the same time 
SCFA and lactate production was stimulated (Fig. 2.2 and Table 2.2, respectively). Since BCFA, 
ammonia, and phenolic compounds are products typical of breakdown and fermentation of proteins 
it can be concluded that inulins inhibit the proteolytic activity of the colonic microbiota and 
stimulate the saccharolytic activity, as indicated by the increased SCFA and lactate production. 
With C. difficile introduced into the model, the effects of inulin became even more pronounced. The 
increase in proteolytic activity caused by C. difficile was suppressed to a large extent by the 
addition of the inulins, irrespective of the chain length. These results corroborate the hypothesis that 
fermentable fibres, such as inulin, decrease the amount of protein fermentation products by 
repressing protein fermentation itself. In an in vitro batch incubation, a reduction of phenol and p-
cresol production by 63% and 78%, respectively, was observed during fermentation of a readily 
fermentable source of carbohydrate (starch) by human faecal bacteria (26). Instead of being 
fermented, the amino acids and ammonia are incorporated into the bacterial biomass; Levrat et al. 
(28) observed an increase in the use of ammonia by the microbiota of rats after the addition of 
inulin to their diet.  
Our results demonstrate clearly the potential of inulins to shift the metabolic activity of the human 
colonic microbiota into a direction resulting in the production of potentially less toxic products, 
without major changes in the composition of this microbiota. For the inulins with varying DP 
grossly similar effects were found for the potential to induce changes in the metabolism of the 
colonic microbiota in this system. So the prebiotic activity (i.e. the ability to bring about a 
metabolic shift) of the various inulins seems to be relatively independent of the chain length. This 
may seem surprising in view of the differences reported for the bifidogenic effects of inulins in 
relation to chain length, with DP3-inulin suggested to be more effective than DP25-inulin (29). 
However, in the present study we could not find a major difference for the changes in metabolic 
activity brought about by the different inulins. Our hypothesis is that the complex microbiota 
present in TIM-2 is equally able to ferment long-chain inulin as short-chain inulin. We propose that 
endo-inulinase activity quickly reduces long-chain inulin into short-chain molecules. It may well be 
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that different species are responsible for the fermentation of different inulins, but that the overall 
metabolic effect is the same. 
The introduction of only a small number of C. difficile bacteria (only about 1% or less of the total 
bacterial population was added) caused a major shift in the overall metabolism of the colonic microbiota 
towards proteolysis. The fact that the number of C. difficile did not change after inulin addition is 
probably due to the constant pH of the system, as May et al. (30) suggested that a decrease in pH is 
necessary to inhibit C. difficile growth. Apparently, the metabolic balance, disturbed by the introduction 
of C. difficile, cannot be restored by the microbiota alone, since there was no normalisation of the 
metabolism during the time course of these experiments without addition of inulins. For instance, the 
cumulative production of ammonia in time remained virtually unchanged (Fig. 4). Apparently, the 
addition of e.g. inulins is required to shift the metabolism from proteolysis to saccharolysis. Similar data 
were found by Terada et al. (31) following lactulose consumption by human volunteers. Lactulose 
consumption suppressed the formation of proteolytic products in faeces (31). In addition, Hidaka et al. 
(32) found similar results in a human study: consumption of short-chain inulins (DP3-inulin) led to a 
decrease in the faecal concentrations of BCFA and phenolic compounds. 
Since we used samples of a standardized faecal microbiota (grown in a fed-batch fermentor) as 
inoculum, the results of the different experiments can be properly compared. We have previously shown 
that the microbial composition and activity of the inoculum did not differ substantially from that of the 
fresh faecal microbiota ((23,24) and data not shown). Therefore we presume that the results as presented 
reflect the possible in vivo effects of inulins or a C. difficile infection.  
The mechanism causing the differences in metabolic activity between the C. difficile containing 
microbiota with and without the addition of inulin is postulated to be that the inulins also provide a 
suitable carbon source for the C. difficile bacteria, thus preventing protein fermentation. The C. 
difficile strain used in this study was able to ferment the inulins used in this study (unpublished 
observations) and it is known that C. difficile VPI 10463 can grow on short-chain inulins (31). 
Since clostridia are involved in butyrate production, the observation of a higher relative amount of 
butyrate with DP3- and DP-25 inulin in combination with C. difficile is in accordance with the 
proposed mechanism described above. 
The cause of the decreased propionate production after addition of C. difficile or its restoration after 
inulin addition remains obscure. It could well be that the increased lactate formation following the 
addition of inulins (Table 2.2) leads to an increased propionate formation (33), but the reduction of 
propionate production remains unexplained. 
The results show that even in a microbiota originating from healthy humans, a low intake of proteins 
(approximately 5 g/day in the present study) can result in the production of potentially toxic or harmful 
metabolites. Since the model represents the proximal colon, this indicates that even in a region of the 
gut where protein fermentation is of minor importance these substances can be produced. Inulins can 
reduce this production, whereas addition of the C. difficile can stimulate it. It is of general interest to 
determine whether individuals with chronic bowel problems, such as inflammatory bowel disease 
patients, show evidence of an altered metabolic function of the microbiota in the large intestine and 
whether this is related to the onset or progression of the disease. Dietary interventions in these patients 
may have the same effect on the metabolic activity of the microbiota as that shown for healthy 
individuals. We are currently investigating this. 
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The relevance of these findings is that the prebiotic action of inulin clearly is not limited to a mere 
(bifidogenic) change in the composition of the colonic microbiota, but includes a shift in metabolic 
activity; from proteolysis to saccharolysis. It is certainly a feature of the in vitro system employed in this 
study that such an effect can be found. In vivo, adequate sampling is impossible, since one can only take 
faecal samples from which most of the fermentation products (SCFA, ammonia) will already have been 
absorbed by the body (34,35). It is therefore not surprising that others could not find a change in faecal 
SCFA after consumption of inulin by human volunteers despite a significant bifidogenic change in 
bacterial composition of the faecal microbiota (6,34). Similarly, we have found no changes in faecal 
SCFA after lactulose treatment, whereas the SCFA production in TIM-2, simulating the proximal colon, 
did change (36). 
The effect on metabolic activity seems much more relevant for any potential health implication of 
the use of inulins in food than a mere shift in bacterial composition. Model studies such as those 
reported here may prove to be an important tool for establishing the effects of (potential) prebiotic 
ingredients on the metabolic activity of the colonic microbiota. The model has already been used 
with cultivated human microbiota from healthy individuals to simulate conditions in the proximal 
colon (24). From the present study it can be concluded that this in vitro model of the large intestine 
can also be used to study the effects of prebiotics in the gastrointestinal tract of humans infected 
with a pathogen or with a disturbed microbiota.  
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Abstract 
The hypothesis was studied that intestinal microbial metabolites play a role in the pathogenesis of 
inflammatory bowel disease. For that purpose, an in vitro model of the colon was inoculated with 
fresh feaces of 6 healthy individuals and 8 inflammatory bowel disease patients. Samples were 
taken from the model over time to analyze metabolites from both saccharolytic- and proteolytic 
fermentation. Microbiotas from inflammatory bowel disease patients produced significantly more 
short-chain fatty acids and ammonia than microbiotas from healthy individuals. Furthermore, the 
branched-chain fatty acid production was 25% higher after inoculation with microbiotas from 
patients than after inoculation with microbiotas from healthy individuals. Phenolic compounds were 
produced by all microbiotas with large interindividual variation. The production of (potentially 
toxic) metabolites may play a role in the onset or chronicity of inflammatory bowel disease, because 
they were produced in higher amounts by microbiotas from these patients than by microbiotas from 
healthy individuals. 
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Introduction 
Ulcerative colitis (UC) and Crohn’s disease (CD) are intestinal inflammatory disorders with 
unknown ethiology. Inflammatory bowel disease (IBD), the collective term for UC and CD, is 
possibly caused by a disregulated immune response to antigens of the enteric bacterial microbiota in 
a genetically susceptible host (1,2). In this hypothesis, host genetics, immune response, and 
bacterial microbiota are inextricably linked. It is unknown whether patients with IBD have an 
altered metabolic function of the intestinal microbiota and whether this is related to the severity of 
the disease. Currently, two hypotheses regarding the role of microorganisms in IBD are under 
investigation. The first suggests that specific microorganisms play a role in the induction of 
inflammation (3-7). The second suggests that metabolites derived from the microbiota, without 
regard to species, can be mediators of injury and inflammation (8,9).  
Colonic fermentation is an anaerobic process in which carbohydrates and proteins are metabolized 
by the large intestinal microbiota to salvage energy (10). This process is regulated by the 
composition of the colonic microbiota as well as by the amount and type of substrate that enters the 
colon, consisting of dietary residues and host-produced substances (8,10-12). Protein fermentation, 
in particular, gives rise to a variety of metabolites that are potentially toxic, including phenolic 
compounds, branched-chain fatty acids (BCFA), and ammonia (10,13). However, little is known 
about their production and their biological role in vivo. The within-subject variation turned out to be 
high in studies using colonic contents (8) or feaces (12) to determine concentrations of phenol, p-
cresol, BCFA, and ammonia, respectively indole and skatol. Studies focussing on metabolites in 
different regions of the colon showed that the proteolytic activity of gut bacteria is higher in the 
distal parts, where pH is increasing (4,8,14). The protein fermentative metabolites have been 
associated with a variety of disease states in humans, including schizophrenia and cancer. They 
seem to have several cytopathic effects on colonic epithelial cells, including reduction of their 
lifespan (4). Protein fermentation potentially plays a role in IBD by causing damage to epithelial 
cells in genetically susceptible hosts, resulting in inflammatory reactions. 
Besides a higher proteolytic activity, a lower saccharolytic activity can possibly also influence the 
pathogenesis of IBD. Especially depletion of butyrate or prevention of the oxidative use of butyrate 
by epithelial cells (e.g. by sulphur compounds) leads to loss of integrity of these cells and, 
eventually, results in death and epithelial desquamation. The latter is presumably the case in UC 
patients (15,16). Renewal of the lost cells increases proliferation and may eventually influence the 
chance of cancer development (17). In addition, the increased desquamation and a lack of short-
chain fatty acids (SCFA) lead to a decreased barrier function and make the colonic epithelium more 
susceptible to inflammation (18). Furthermore, the presence of carbohydrates influences proteolytic 
fermentation. Fermentation of carbohydrates, resulting in a pH decline, reduced production of 
phenol and p-cresol in vitro, by 63% and 78%, respectively (14), and led to an increased use of 
ammonia for use in biosynthetic reactions of the microbiota (4,8). We recently showed that inulins 
can reduce the production of protein fermentative metabolites (19). 
Feaces is not a good indicator of the fermentative activity that occurs in the proximal colon (20). 
For IBD patients, investigating faecal material is even more complex. Damage to the mucosa of 
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IBD patients caused by inflammations can result in inadequate absorption and utilization of 
metabolites and therefore results in higher concentrations of metabolites in their feaces than in that 
of healthy individuals (21). With feaces, no distinction can be made between the above-mentioned 
theory and an actual altered metabolic functioning by luminal bacteria from IBD patients. The goal 
of this study was to determine whether patients with IBD show evidence of an altered metabolic 
function of the microbiota in the proximal colon. This was studied in an in vitro model of the 
proximal colon.  
Materials and Methods 
Faecal microbiota 
Six healthy individuals (aged 23-31 years) and eight IBD patients with colitis in remission, five 
with CD affecting the colon and three with UC, aged 28-53 years, were studied. The six healthy 
volunteers (H1–H6) and two of the CD patients (IBD1 and IBD2) had not taken any medication or 
probiotics in the 6 months prior to study. The other IBD patients (IBD3–IBD8) had not taken 
probiotics, but were treated with mesalazine (n=4) and corticosteroids (budenoside, n=4; prednison, 
n=3). 
An early-morning faecal sample was collected from each subject at home and immediately placed 
into gastight bags containing an Anaerocult® strip to create anaerobic conditions during transport to 
the anaerobic cabinet. This transport never lasted longer than 3 h. A faecal sample of approximately 
30 g was mixed with artificial ileal delivery medium (80 mL; see Gibson et al. (22) and van Nuenen 
et al.(19)) in an anaerobic cabinet to get a solution resembling the content of the human, proximal 
colon. These mixtures were used as inocula for TNO’s in vitro model of the large intestine (TIM-2).  
Experiments in TNO’s in vitro model of the large intestine (TIM-2) 
Details of the in vitro model (TIM-2, Figure 3.1) are given by Minekus et al. (23) and Venema et al. 
(24). In short, TIM-2 is a computer controlled in vitro model that simulates the human proximal 
colon (23). It consists of a number of linked glass units with inner flexible walls. Water at 37°C can 
be pumped into the space between the glass jacket and the flexible wall, yielding peristaltic 
movements and causing the content to be mixed and moved. Appropriate electrolyte and metabolite 
concentrations in the lumen were maintained with a dialysis system consisting of hollow-fibres, 
running through the lumen, through which dialysis liquid (22,19), was pumped. The model further 
contained an inlet system for delivery of the artificial ileal delivery medium, and a level-sensor to 
maintain the luminal content at a set level. The system was kept anaerobic by flushing with gaseous 
nitrogen, to allow for the growth of a dense, complex microbiota, comparable in composition and 
activity to that found in humans in the proximal colon (24). The model enabled the study of 
metabolic activity of the colonic microbiota under physiological circumstances. 
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During each experiment, the TIM-2 system was inoculated with the mix of fresh feaces and ileal 
delivery medium, from a single study subject. The microbiota was allowed to adapt to the model 
conditions for 16 h, after which the actual experimental period (48 h) started. In all experiments the 
pH was maintained at 5.8 by titration with 2 M NaOH, the temperature was kept at 37°C, and the 
microbiota was fed semi-continuously (4.6 mL/h) with the ileal delivery medium. To simulate 
bowel movements, 30 mL of contents was removed from the model twice daily. In the luminal 
samples and samples of the dialysis liquid, taken at 16, 40, and 64 h after inoculation, the 
concentrations of the various metabolites were determined as described below. With these data and 
the known volume of the dialysis liquid, cumulative productions over time were calculated (mmol 
or µmol).  
Analyses 
SCFA, BCFA and lactate 
SCFA (acetate, propionate, butyrate, valerate) and BCFA (iso-butyrate and iso-valerate) analysis 
were performed on a gas chromatograph (Chrompack CP9001; Varian Chrompack, Bergen op 
Zoom, the Netherlands) essentially according to the method described by Jouany (25). After 
centrifugation of the samples (12,000 rpm, 5 min), the clear supernatant was diluted (7%, by 
volume) with a mixture of methanol, internal standard (2 mg/mL 2-ethyl butyric acid) and formic 
acid (20%). Of this mixture 0.5 µL was loaded onto a “wide-bore” GC column (Stabilwax-DA; 
length, 15 m; ID, 0.53 mm; film thickness, 0.1 µm; Varian Chrompack) using an automatic sampler 
(Chrompack CP9050; Varian Chrompack).  
Samples for lactate analysis were centrifuged as described for SCFA analysis. In the clear 
supernatant both L- and D-lactate were determined enzymatically (based on Boehringer, UV-
Figure 3.1 Schematic representation of 
the large intestinal model TIM-2.  
a: peristaltic compartments containing 
fecal matter; b: pH-electrode; c: alkali 
pump; d: dialysis liquid circuit with 
hollow fibres; e: level-sensor; f: N2 gas 
inlet; g: in- or outlet valves;  
h: sampling-port; i: gas outlet; j: 'ileal 
delivery' container. 
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method, Cat. No. 1112821) by a Cobas Mira plus autoanalyzer (Roche, Almere, the Netherlands). 
The analysis is based on the conversion of NAD into NADH. 
Phenolic compounds  
Phenolic compound analyses (phenol, p-cresol, indole, skatol) were performed on a gas 
chromatograph based on methods described previously (14,26-29). For extraction of the phenolic 
compounds, 0.5 mL of chloroform was added to the samples. After mixing well, samples were 
centrifuged (4,500 rpm, 5 minutes). Fifty µL of the chloroform phase was diluted with methanol 
(1:10). To the diluted sample, 100 µL internal standard (p-nitrophenol; 1.5 mg/mL in methanol) was 
added. Of the mixture obtained, 0.5 µL was loaded onto a WCOT Fused Silica GC column (length, 
25 m; ID, 0.53 mm; film thickness, 1 µm; Varian Chrompack) using the automatic sampler.  
Ammonia 
Ammonia was measured with an ammonia selective electrode (Orion, Beverly, CA, USA), after the 
addition of an ionic strength adjustor (ISA) to raise the pH above pH 12. This turned the NH4+ ions 
into gaseous NH3. The electrode measured the released gas, and concentrations in the samples were 
determined via comparison with a series of standard solutions with known concentrations.  
Statistical analyses 
Statistical analyses were performed using the Student’s t-test. A p ≤0.05 was considered significant.  
Results 
SCFA production 
The total cumulative SCFA production ranged from 98 to 137 mmol in the eight IBD patients 
(mean, 115 mmol; SD, 11.2 mmol; Table 3.1), whereas production ranged from 63 to 102 mmol for 
microbiotas from healthy individuals (mean, 89 mmol; SD, 16 mmol). IBD patients produced a 
significantly higher amount of SCFA than healthy individuals (p=0.0036). In four controls and all 
eight IBD patients acetate production was higher than that of other SCFA (Table 3.1); two healthy 
individuals (H3 and H6) produced more butyrate.  
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Table 3.1 SCFA ratios (%) and total cumulative production (mmol) by different types of fresh feaces after 
64 h of fermentation in TIM-2.  
Individual C2 (%) C3 (%) C4 (%) Total (mmol)
IBD1 53 24 23 137 
IBD2 64 12 25 107 
IBD3 46 26 28 119 
IBD4 54 21 25 98 
IBD5 46 17 37 116 
IBD6 57 17 26 112 
IBD7 55 24 22 118 
IBD8 44 32 25 116 
H1 52 16 32 99 
H2 50 21 29 98 
H3 37 23 40 98 
H4 38 29 33 63 
H5 49 21 30 102 
H6 20 22 58 76 
 
Lactate production 
Lactate production did not differ between IBD patients (mean, 2.1 mmol; SD, 1.5 mmol) and 
healthy individuals (mean, 1.9 mmol; SD, 0.9 mmol; Table 3.2). Total lactate production after 64 h 
ranged from 0.01 to 3.97 mmol and the amount of D-lactate was always almost twice as high as that 
of L-lactate (except for individual IBD6; Table 3.2).  
Table 3.2. Ratios (%) and total production (mmol) of L- and D-lactate by different types of fresh feaces after 
64 h of fermentation in TIM-2. 
Individual L (%) D (%) Total (mmol) 
IBD1 33 67 3.70 
IBD2 33 67 3.97 
IBD3 27 73 1.84 
IBD4 28 72 1.19 
IBD5 31 69 1.87 
IBD6 0 100 0.01 
IBD7 48 52 3.90 
IBD8 44 56 0.50 
H1 36 64 1.37 
H2 34 66 1.08 
H3 35 65 2.78 
H4 38 62 2.64 
H5 34 66 2.62 
H6 28 72 0.76 
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BCFA production 
The cumulative production of BCFA is shown in Figure 3.2. As of the start of all experiments 
BCFA production was rather stable. Overall, the healthy individuals (mean, 3.80 mmol; SD, 1.45 
mmol) had an in vitro BCFA production that was 25% lower (p=0.053) than that of the IBD 
patients (mean, 5.10 mmol; SD, 0.81 mmol). Cumulative production was highest for patient IBD3 
(5.88 mmol) and lowest for control H6 (1.62 mmol; Figure 3.2). The ratio for iso-butyrate versus 
iso-valerate in TIM-2 was 40:60 in all experiments (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Total cumulative BCFA production (mmol; sum of iso-butyrate and iso-valerate) by different 
types of fresh feaces, during 64 h in TIM-2. 
Ammonia production 
Ammonia production was stable during the course of the experiments (Figure 3.3). On average, the 
healthy individuals produced significantly less ammonia than the IBD patients (28 mmol; SD 8.3 
mmol versus 42 mmol; SD 6.3 mmol; p=0.0034). Individual IBD6 produced the highest cumulative 
ammonia amount (47 mmol). The lowest production was 16 mmol, by individual H6.  
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Figure 3.3 Total cumulative ammonia production (mmol) by different types of fresh feaces, during 64 h in 
TIM-2. 
Phenolic compounds production 
Only indole and p-cresol were produced in all TIM-2 experiments. Phenol and skatol production 
was rare. Overall, production of phenolic compounds was not stable during the two experimental 
days (Figure 3.4). Furthermore, both cumulative production and the ratios of the compounds 
differed widely between subjects within one group (IBD, SD = 62% of mean; healthy, SD = 81% of 
mean). Cumulative production after inoculation of TIM-2 reached various levels, from 21 to 203 
µmol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Total cumulative phenolic compounds production (µmol; sum of phenol, p-cresol, indole, and 
skatol) by different types of fresh feaces, during 64 h in TIM-2. 
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Discussion 
Microbes and their metabolic products very likely play a role in IBD. This hypothesis is based on 
various arguments, obtained both in humans and in animals, including the effect of deviation of the 
faecal stream on disease activity in CD. Unfortunately, there is a lack of solid data to substantiate 
the hypothesis. This is primarily due to the fact that the study of microbial metabolic activity is 
difficult, for among others, reasons of sampling and difficulty mimicking physiological 
circumstances ex vivo. Our TIM-2 system overcomes these difficulties and is therefore relevant for 
the study of microbial metabolic activities (19,23,24,30). The goal of this study was to determine 
whether patients with IBD show a different metabolic activity of the microbiota in the proximal 
colon in comparison with healthy controls. We observed higher production of short- and branched-
chain fatty acids, as well as ammonia, in the experiments using feaces of IBD patients compared to 
that of controls. These differences were not observed for the production of phenolic compounds and 
lactate, which varied greatly. Furthermore, standard deviations for all determined metabolites 
(except lactate) were smaller in the IBD group than in the healthy control group, which is 
surprising, considering the differences in disease course and use of medication in the IBD patients. 
The higher metabolite production in IBD patients is in agreement with literature data obtained with 
other methods (16,21,31). 
These data suggest that increased metabolite concentrations may affect IBD. The cause of the 
higher metabolic activity in these patients is unknown. It seems unlikely that only damage to the 
mucosa, resulting in inadequate absorption of these metabolites, is the cause of the increased 
metabolite concentrations. 
Our results may have been influenced by a number of potential confounders. During the 64 h of 
fermentation in TIM-2, the pH was set at 5.8. This is the pH in the proximal colon of healthy 
individuals (32). No extensive research is done in IBD patients concerning the pH in (this part of) 
the colon. Another debatable point is the digestion of food in the stomach and small intestine; if this 
function of the gastrointestinal tract in IBD patients also deviates from healthy individuals, the IBD 
microbiota in TIM-2 are fed other substrates than in vivo, which will result in different metabolite 
profiles. Without extensive knowledge of the environmental circumstances in the proximal IBD 
colon, our results here may not totally reflect the events in vivo.  
The proteolytic activity of the gut microbiota can increase remarkably, even by a factor of 5, in the 
distal colon compared to the proximal colon (4,14,33). Therefore fermentation in the transverse and 
descending parts of the colon will give more insight into the colonic health status. An in vitro 
system simulating this distal part, with physiological parameters such as lower water content and a 
higher pH, is in development at our institute and will be used in the future to study the metabolic 
activity of microbiotas obtained from IBD patients under relevant physiological conditions. 
Our results show also that feeding microbiotas of healthy humans approximately 5 g of protein per 
day, which is only one third of the estimated amount that becomes available in the proximal colon 
in vivo (34,35), results in production of detectable amounts of potentially toxic or harmful 
metabolites, even when the environmental conditions mimic those of the healthy proximal colon. 
The ability of the colonic mucosa to detoxify these substances seems to be impaired in UC (14), 
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causing the colonic tissue of patients to be more susceptible to the toxicity of these compounds than 
colonic tissue of healthy individuals. If so, the microbial activity in the colon of IBD patients can 
certainly serve as an indicator of disease severity. However, without ex vivo or in vivo tests on the 
toxicity of these compounds, we cannot conclude which metabolites (and at which concentrations) 
cause injury to the epithelial barrier of IBD patients.  
Once the role of the metabolic activity of IBD microbiotas has become more clear, dietary 
interventions of IBD may become feasible. The effect of pre- and probiotics and other (functional) 
food components on the composition and metabolic activity of different microbiotas are currently 
being studied in our institute. 
In conclusion, we demonstrated that the colonic microbiota from IBD patients produced 
significantly more short- and branched-chain fatty acids, as well as ammonia, than microbiotas from 
healthy individuals. The production of (potentially toxic) metabolites may play a role in the onset or 
chronicity of IBD because they are produced in higher amounts by microbiotas from these patients 
than by microbiotas from healthy individuals. 
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Abstract 
Microbial metabolites may influence the metabolic integrity of intestinal epithelial cells and induce 
mucosal immune responses. Therefore we investigated the effects of the microbial metabolites 
butyrate, iso-valerate, and ammonium on Caco-2 cells and macrophages. Barrier functioning was 
determined by measuring transepithelial electrical resistance and basolateral recoveries of 
metabolites. Tumour necrosis factor-α and interleukin-10 were measured to determine immune 
reactions. The barrier function of Caco-2 cells remained intact after exposures. Basolateral 
recoveries ranged from 6.2% to 15.2%. The Caco-2 cells did not secrete both cytokines. 
Physiological concentrations of butyrate and iso-valerate stimulated the secretion of tumour 
necrosis factor-α and suppressed the secretion of interleukin-10 by macrophages that are not 
protected by an epithelial barrier. In contrast, ammonium concentrations as high as those produced 
by microbiotas of IBD patients suppressed the release of both cytokines when the barrier function is 
impaired. 
Microbial metabolites, epithelial cells & macrophages 
65 
Introduction 
An intact gastrointestinal mucosa, with a normal intestinal permeability and barrier function, is 
essential for absorption, secretion and transport. Intestinal epithelial cells (IEC) that line the 
gastrointestinal mucosa can be regarded as the most outer defence barrier preventing 
microorganisms and endotoxins from reaching systemic organs and tissues (1-4). 
The relation between IEC, luminal microbiota, and inflammatory bowel disease (IBD) appears 
evident. Intestinal epithelial cells play an important role in the interaction between luminal content 
and the host’s immune system (2,3,5), while a role for microbiota in triggering the inflammatory 
process has been proposed (6-8). Both luminal microorganisms and their metabolites can possibly 
influence the metabolic integrity of the IEC, resulting in presentation of these antigens to the 
mucosal immune system (9-11). 
The mucosal immune system controls the production of cytokines. CD4+ T-helper (TH)-1 cells 
mediate cellular immunity and macrophage activation. Activated macrophages produce 
proinflammatory cytokines, including TNF-α. TH-2 cells mediate humoral immunity and produce 
anti-inflammatory cytokines, including IL-10. In IBD, the TH-1/ TH-2 balance is disturbed. An 
increase in TH-1 cytokines is detected in Crohn’s disease (CD) patients, whereas in patients affected 
by Ulcerative colitis (UC) TH-2-like immune activation has been demonstrated (10,12). 
In a previous study an in vitro colon model was used to study the role of microbial metabolites in 
the pathogenesis of IBD. Microbiotas from IBD patients produced significantly more short-chain 
fatty acids (SCFA, including butyrate) and ammonium than microbiotas from healthy individuals. 
Furthermore, the branched-chain fatty acid (BCFA, iso-butyrate and –valerate) production was 25% 
higher after inoculation with microbiotas from patients than after inoculation with microbiotas from 
healthy individuals (13). Butyrate is a major source of energy for colonic epithelial cells. Depletion 
of butyrate leads to a decreased barrier function and results in a higher susceptibility of the colonic 
epithelium to inflammation (10,12). UC may be associated with a mucosal defect in the metabolism 
of butyrate (3). BCFA and ammonium are potentially toxic (on colonic epithelial cells), although 
little is known about their biological role in vivo (14).  
We hypothesized that the increase in production of microbial metabolites contributes to IEC injury 
and/or loss of the integrity of the barrier function in IBD. Enhanced presentation of these microbial 
metabolites to the mucosal immune system may then play a role in the maintenance of IBD activity. 
We investigated which metabolites, and at which concentrations, cause injury to epithelial cells and 
thereby might modulate unwanted immune reactions. This was studied by co-culturing enterocyte-
like Caco-2 cells with macrophages in separate compartments of a TranswellTM system. In addition, 
the direct effect of metabolites on Caco-2 cells and macrophages was tested. 
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Materials and Methods 
Culture systems 
Caco-2 mono-culture 
Human colon carcinoma Caco-2 cells (ATCC; Rockville, MD, USA) were cultured (37°C; 5% 
CO2) in medium A: Dulbecco’s Modified Eagle Medium, 4.5 g/L glucose, 1% (v/v) MEM non-
essential amino acids (100x), 25 mM HEPES, 2 mM L-glutamine, 0.5% 50 mg/mL gentamycin (all 
from Life Technologies BV, Breda, The Netherlands), 10% (v/v) fetal calf serum (Cambrex Bio 
Science, Verviers, Belgium). This medium was changed every 2-3 days. Caco-2 cells were then 
seeded (105 cells/cm2) in TranswellTM polycarbonate cell culture inserts (12 well) with a mean pore 
size of 0.4 µm (Corning Inc, Schiphol, The Netherlands) and cultured for 15 to 21 days to obtain 
differentiated monolayers (15). 
U937 mono-culture 
Human monocyte-like histiocytic lymphoma U937 cells (ATCC; CRL-1593.2, Manassas, VA, 
USA), were grown (37°C; 5% CO2) in medium B: RPMI-1640 medium (Life Technologies BV), 
10% (v/v) fetal calf serum (Cambrex Bio Science), and 2 mM L-glutamine (Life Technologies BV). 
The U937 cells were seeded in 12-wells plates (2*106 cells/well) and differentiated overnight into 
macrophages using phorbol 12-myristate 13-acetate (PMA, 10 ng/mL; Omnilabo, Breda, The 
Netherlands). Before exposure to the microbial metabolites (see below), the macrophages were 
allowed to recover from PMA treatment for 48 h, during which culture medium was replaced every 
day (16).  
Co-culture model 
TranswellTM inserts covered with differentiated Caco-2 cells were transferred to 12-well culture 
plates seeded with macrophages. Before transfer, transepithelial electrical resistance (TEER) was 
measured (see below) and medium A was removed from the inserts (apically). Medium B, used in 
the basolateral compartment of the co-culture model, was refreshed before the Caco-2 inserts were 
placed into the compartments. 
Exposure to microbial metabolites 
Sterile stock solutions of single sodium salts of butyrate (C4) and iso-valerate (i-C5), and 
ammonium (NH4+)-chloride were prepared in medium A (Caco-2 mono-cultures and co-cultures) or 
medium B (U937 mono-cultures). Concentrations of the metabolites tested were based on 
experiments in TNO’s in vitro model of the colon in which faeces from IBD patients or healthy 
volunteers was used as inoculum (13). Cell viability was determined by cytotoxicity tests (MTT) 
prior to the actual exposures (data not shown). 
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Caco-2 mono-culture 
Caco-2 mono-cultures were exposed to microbial metabolites to determine 1) injury or loss of 
barrier function and 2) cytokine production, possibly interfering with the cytokine production by 
macrophages. 
Injury or loss of barrier function were determined by measuring transepithelial electrical resistance 
(TEER) and basolateral recoveries of the used metabolites. Concentrations of C4, i-C5, and NH4+ 
were tested in triplicate (pH 6.3-7.3; 10-100 mM) to determine dose-response curves. After the 
addition of metabolite solutions to the apical compartment of Caco-2 monolayers (TEER>500 
Ω*cm2), TEER was measured for a 24 h period (at 0, 0.5, 1, 2, 4, 6, and 24 h) using a Millicel-ERS 
epithelial voltohmmeter with Ag/AgCl electrodes (Millipore, Bedford, USA) in iso-osmotic 
(approximately 300 mOsm) media. Metabolites were measured before and after 6 h of exposure of 
the Caco-2 mono-cultures to calculate mass-balances. 
To determine TNF-α and IL-10 secretion by Caco-2 cells upon exposure to microbial metabolites, 
the following solutions were tested: 50, 100, and 100 mM + lipopolysaccharide (LPS, 1 µg/mL; 
Sigma-Aldrich, Zwijndrecht, The Netherlands) C4 and i-C5 and 40, 60, 20 mM + LPS, and 40 mM 
+ LPS NH4+. Samples were taken after 6 h of incubation (37°C; 5% CO2) to determine TNF-α and 
IL-10 concentrations by ELISA using CytoSet™ antibody pairs (Biosource, Nivelles, Belgium), 
according to the instructions provided by the manufacturer.  
U937 mono-culture 
U937 mono-cultures were directly exposed to C4, i-C5, and NH4+ to determine the effect on 
cytokine production. Concentrations varied from 2 to 100 mM (see Figures 4.1 and 4.2) to mimic 1) 
a situation in which the macrophages are protected by a barrier (the results of the Caco-2 mono-
culture experiments revealed that 6.2-15.2% of the initial amounts of microbial metabolites (20–100 
mM) appeared on the basolateral side) and 2) a situation in which the barrier function of the 
epithelium was abolished. Metabolites were measured before and after 6 h of exposure of the U937 
mono-cultures to calculate mass-balances. 
Samples of culture medium were collected after 6 h of incubation (37°C; 5% CO2) to determine 
TNF-α and IL-10 secretion. U937 macrophages, exposed to LPS, have an optimal secretion of TNF-
α and IL-10 at t=6 h, thereafter secretion diminishes (data not shown). 
Co-culture model 
In the co-culture model experiments, the combined effect of microbial metabolites and a Caco-2 
barrier on macrophages was investigated. Butyrate, i-C5, or NH4+ were added for 6 h (t0-t6) to the 
apical compartments of the co-culture model (C4 and i-C5: 50 and 100 mM; NH4+: 20, 40, and 60 
mM). Subsequently, the macrophages were incubated for another 6 h (t6-t12) in the presence of 
LPS (1 µg/mL). Samples of the culture medium were collected after 6 and 12 h to determine the 
TNF-α and IL-10 secretion. The TEER of the Caco-2 inserts was measured at t0 and t6. Test 
solutions were analysed for concentrations of metabolites before exposure of the co-cultures, after  
6 h of co-incubation (apical and basolateral), and after another 6 h (t6-t12) of incubation of the 
macrophages with LPS to calculate mass-balances. 
Chapter 4 
68 
All microbial metabolites were measured as described before (17). 
Statistical Analysis 
Results are expressed as means (± SD when n>2 or range when n=2). Comparison of TEER and 
release of cytokines between (positive) control samples and samples exposed to microbial 
metabolites were performed using ANOVA and Student’s t-test. A p≤0.05 was considered 
significant. 
Results 
Integrity of the barrier function 
TEER 
The TEER was expressed as % of the value of the same well prior to exposure (Table 4.1). In the 
Caco-2 mono-culture experiments, exposure to C4 or i-C5 did not induce a functional loss of, or 
have a dose-dependent effect on the barrier function, except at the highest concentration tested (100 
mM). In the latter cases, the average TEER dropped significantly compared to the other 
concentrations tested, as well as compared to the control (p<0.001 in all cases). After exposure to 
ammonium, the average TEER value declined to 75% (± 11%), which was significantly lower than 
the control (p=0.010). No concentration-effect could be detected. The addition of LPS to a 
microbial metabolite solution had no effect on TEER (data not shown).  
No functional loss of the barrier function was found with any of the concentrations of C4, i-C5, and 
NH4+ tested in the co-culture model experiments. The average TEER value of the Caco-2 cells in 
the co-culture model was significantly higher (p=0.016) than that of Caco-2 cells in a mono-culture 
model after 6 h of incubation with medium A (Table 4.1). Furthermore, TEER values were 
significantly higher when Caco-2 cells were exposed to C4-100 and i-C5-100 in a co-culture model 
compared to exposure of these cells in a mono-culture model (p=0.004 and p=0.037, respectively). 
In addition, the effect of NH4+ was less pronounced in co-culture incubations compared to mono-
culture incubations. 
Mass-balances of metabolites 
In the Caco-2 mono-culture experiments, 7.4% (± 1.1%), 10.8% (± 2.1%), and 11.2% (± 3.1%) of 
the initial amounts of C4, i-C5, and NH4+, respectively, were recovered from the basolateral side. 
With macrophages underneath the Caco-2 cells, the average basolateral recovery after 6 h was 6.4% 
(± 0.8%) for C4, 6.2% (± 0.6%) for i-C5 and 15.2% (± 6.8%) for NH4+. The sum of the apical and 
basolateral recovery was in both types of experiments less than 100% of the initial amounts. The 
initial amounts of all metabolites tested on U937 cells of both the mono- and co-culture models 
were fully recovered after 6 h of incubation. 
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Table 4.1. Transepithelial electrical resistance of Caco-2 cells. 
CACO-2 mono-culture CACO-2 co-culture 
Metabolite-mM TEER a SD Metabolite-mM TEER a SD 
C4-25 98 7.3 C4-50 94 17.7
C4-65 103 19.6 C4-100 88 7.7
C4-85 99 6.8 i-C5-50 105 11.0
C4-100 68 1.1 i-C5-100 84 14.7
i-C5-30 95 2.1 NH4+-20 94 12.7
i-C5-60 101 5.9 NH4+-40 83 20.1
i-C5-90 93 2.7 NH4+-60 106 22.9
i-C5-100 64 6.4 Medium A 101 10.2
NH4+-10 74 17.4    
NH4+-20 76 4.5    
NH4+-40 77 1.2    
Medium A 88 6.9    
a TEER values measured after 6 h of exposure, expressed as % of values prior to exposure. Presented are the 
average and standard deviation (SD) of at least three measurements. 
Immune modulations 
Caco-2 mono-culture cells did not secrete detectable levels of TNF-α or IL-10 after metabolite 
exposure (with or without LPS). 
In the U937 mono-culture experiments, addition of 50 and 100 mM C4, or i-C5, or of 20 and 40 
mM NH4+ resulted in dose-dependent inhibition of TNF-α secretion compared to LPS (positive 
control), while lower concentrations (C4, i-C5: 4-20 mM; NH4+: 2 and 4 mM) stimulated TNF-α 
secretion (dose-independent; Figures 4.1A, B, and C for C4, i-C5 and NH4+, respectively). IL-10 
secretion by these macrophages was suppressed by all metabolites in all concentrations compared to 
LPS (dose-dependent; Figures 4.2A, B, and C for C4, i-C5 and NH4+, respectively). The lowest 
concentration of NH4+ (2 mM) was an exception: IL-10 secretion by macrophages exposed to this 
solution was almost twice as high as with LPS.  
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Figure 4.1 TNF-α levels, produced by 
macrophages during 6 h of exposure to 
concentrations of A) butyrate (C4-mM) 
and LPS (1 µg/mL), B) iso-valerate  
(i-C5-mM) and LPS (1 µg/mL), and  
C) ammonium (NH4+-mM) and LPS 
(1 µg/mL). * C4-100 versus LPS and all 
other concentrations tested: p=0.0125.  
† i-C5-50 versus: i-C5-4 - i-C5-20 and  
i-C5-100, p<0.001. †† i-C5-100 versus: i-
C5-4 – i-C5-20, p<0.001; LPS, p = 0.0289. 
††† LPS versus: i-C5-4 - i-C5-20, p<0.001. 
‡ NH4+-2 versus: NH4+-40, p=0.0329; LPS, 
p=0.02549.  
 
Figure 4.2 IL-10 levels, produced by 
macrophages during 6 h of exposure to 
concentrations of A) butyrate (C4-mM) 
and LPS (1 µg/mL), B) iso-valerate 
 (i-C5-mM) and LPS (1 µg/mL), and  
C) ammonium (NH4+-mM) and LPS  
(1 µg/mL). * LPS versus all C4 
concentrations tested: p<0.001. † i-C5-4 
and i-C5-6 versus: all other concentrations 
tested, p=0.0034; LPS, p= 0.0134. †† LPS 
versus: i-C5-10 - i-C5-100, p<0.001.  
‡ NH4+-2 versus: NH4+-4, p=0.0047;  
NH4+-20 and NH4+-40, p<0.001.  
‡‡ NH4+-4 versus: NH4+-20, p=0.0088; 
NH4+-40, p=0.0085. ‡‡‡ LPS versus: 
NH4+-20, p=0.0353; NH4+-40, p=0.0347. 
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Exposure of the Caco-2 cells and the macrophages of the co-culture model for 6 h (t0-t6) to medium 
A without LPS (negative control) resulted in a basolateral secretion of 71.5 pg/mL (± 3.8 pg/mL) 
TNF-α. The average TNF-α secretion after 6 h of exposure to NH4+ was comparable: 73 pg/mL (± 5 
pg/mL). Both C4 and i-C5 on the other hand were able to increase TNF-α secretion in the co-culture 
model significantly (dose-independent; C4: 144.3 pg/mL (± 18.4 pg/mL), p<0.001 and i-C5: 136.2 
pg/mL (± 41.2 pg/mL), p=0.015). Interleukin-10 secretion by the cells of the co-culture model could 
not be detected after 6 h of incubation with the microbial metabolites.  
After removal of the Caco-2 inserts, the macrophages of the co-culture model were incubated for 
another 6 h (t6-t12) with addition of LPS. Compared to LPS, no effects of NH4+ on secretion of 
TNF-α or IL-10 were observed (Figures 4.3A and B). However, C4 and i-C5 both stimulated TNF-α 
secretion significantly (dose-dependent; Figure 4.3A). For IL-10 secretion the opposite effect was 
observed, except for the concentration of 50 mM i-C5. This concentration of iso-valerate stimulated 
IL-10 secretion significantly as compared to LPS (p=0.0053), while C4-50 mM, C4-100 mM and i-
C5-100 mM all suppressed IL-10 secretion by the macrophages significantly (Figure 4.3B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 TNF-α (A) and IL-10 (B) levels, produced by macrophages from the co-culture model during 6 h 
(t6-t12) of exposure. Concentrations of metabolites (mM) given are the concentrations used at the start of the 
co-culture experiments and thus applied at the apical site of the Caco-2 cells. In all cases LPS (1 µg/mL) was 
added at t6. Comparison versus LPS: * C4-50, C4-100, and i-C5-100, p<0.001; i-C5-50, p=0.02.; †C4-50, 
p=0.0039; C4-100, p<0.001; i-C5-50, p=0.0053; i-C5-100, p=0.012.  
Discussion 
The colon of patients with active IBD contains increased concentrations of microbial metabolites 
(13). These metabolites may contribute to the chronic inflammatory process by affecting mucosal 
integrity and by stimulation of macrophages inducing production of pro-inflammatory cytokines.  
In vitro exposure experiments showed that the barrier function of IEC is not easily disturbed by 
microbial metabolites. Exposure to ammonia, or to high concentrations of C4 or i-C5 lowered 
TEER values, but the absolute TEER levels remained higher than 500 Ω*cm2, a level which is 
compatible with an intact barrier function (15). As a result, basolateral recovery of metabolites was 
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in the same order of magnitude in all experiments, regardless of type of experiment, metabolite, or 
concentration of metabolite tested. However, it can not be concluded that intraluminal 
concentrations of C4, i-C5 and NH4+ in IBD patients do not lead to increased permeability of the 
barrier function in vivo because we do not know how sensitive intestinal epithelial cells of IBD 
patients are.  
Information about luminal concentrations of C4, i-C5 and NH4+ in vivo is scarce. Most data are 
traced back from faecal measurements. Especially with IBD patients, faeces is not a good indicator 
of the fermentative activity that occurs in the proximal colon. Damage to the mucosa of IBD 
patients can result in inadequate absorption and utilization of metabolites, resulting in higher 
concentrations of metabolites in their faeces than in that of healthy individuals (18). Two studies 
give some more information of what can be produced in vivo. Cummings et al. (19) and MacFarlane 
et al. (20) measured SCFA, BCFA, and ammonium in colonic luminal contents of sudden-death 
individuals. The intraluminal concentrations of C4, i-C5, and NH4+ in the proximal colon were 38, 
2, and 20 mmol/kg wet weight contents, respectively (20). The observed maximum intraluminal 
metabolite concentrations produced by IBD microbiotas in an in vitro model were approximately 30 
mM for C4, 5 mM for i-C5 and 65 mM for ammonium (13).  
In case of an impaired epithelial barrier, such as in patients with an inflamed ulcerated colon, 
colonic macrophages can be exposed to luminal concentrations of microbial metabolites. Butyrate 
and i-C5 in concentrations that may occur in the colon of IBD patients had a pro-inflammatory 
effect by stimulating the secretion of TNF-α and suppressing the release of IL-10 by macrophages 
that are not protected by an epithelial barrier (U937 mono-culture experiments). In contrast, NH4+ in 
a concentration that may occur in the colon of IBD patients would have an inhibitory effect on 
release of both cytokines. This is speculative, based on Figures 4.1C and 4.2C, because the highest 
concentration tested was only 40 mM. 
Due to the (intact) barrier function of the Caco-2 cells, the TNF-α and IL-10 secretion levels in the 
co-culture experiments reflect the effect of exposure of macrophages to approximately 10% of 
concentrations of initial amounts added to the luminal side. When macrophages are protected by an 
epithelial barrier, ammonium no longer has an inhibitory effect on secretion of TNF-α and IL-10. 
The concentrations of C4 and i-C5 tested in the co-culture experiments are higher than the 
concentrations found in vivo (sudden death individuals) and in vitro (IBD faeces in in vitro model). 
However, butyrate is likely to reach concentrations of 50 or 100 mM, for instance upon 
consumption of prebiotics. Then the effect of this metabolite is pro-inflammatory, even when the 
macrophages are protected by an epithelial barrier (Figures 4.3A and 4.3B). 
Both the supposed positive effect of C4 and the supposed negative effect of NH4+ are not confirmed 
by the present experiments. Our results are contrasting with the limited data available concerning 
butyrate and the production of cytokines: studies with whole-blood models and isolated 
mononuclear cells showed that butyrate (to a maximum of 2 mM) reduced LPS induced TNF-α 
and/or IL-10 production (12,21,22). A complex mixture of microbial metabolites, obtained from 
TNO’s in vitro model of the large intestine, reduced TNF-α and INF-γ, while inducing IL-10 (van 
Nuenen et al., manuscript in preparation). This might indicate that metabolites in combinations 
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might have opposing or synergistic effects. We are currently studying this in more detail, including 
the effect of the cytokines on the barrier function. 
The increased production of C4 and i-C5 by microbiotas of IBD patients, together with an increased 
exposure of the mucosal immune system to these metabolites, due to loss of integrity of the 
epithelial barrier function, contribute to an unwanted immune response. On the other hand, 
ammonium concentrations as high those produced by microbiotas of IBD patients seem to have an 
anti-inflammatory role by suppressing the release of both TNF-α and IL-10 when the barrier 
function is impaired.  
In conclusion, the barrier function of intestinal epithelial cells in vitro is not disturbed by the 
microbial metabolites tested in this study, but these metabolites are able to modulate the secretion of 
both TNF-α and IL-10 by macrophages. The enhanced production of C4 and i-C5 may thus play a 
role in the maintenance of IBD activity. 
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Abstract 
Human interleukin-10 (hIL-10) can be used in the treatment of Crohn’s disease. A new 
development is the targeted delivery of hIL-10 to the site of inflammation by bacteria. We aimed to 
determine whether targeted delivery of hIL-10 producing Lactococcus lactis (L. lactis) could be 
obtained by incorporating the strain in an enteric-coated formulation. Survival and metabolic 
activity of L. lactis was studied in TNO’s in vitro gastrointestinal model, simulating the successive 
dynamic conditions in the stomach and the small intestine, as stationary-phase grown cells or after 
incorporation in two types of enteric-coated formulation (one disintegrating at a pH of 6.0 and 
higher; another disintegrating at a pH equal or higher than 7.2). Only 0.04% of the stationary-phase 
grown cells was recovered after oral intake. Incorporating L. lactis in enteric-coated capsules 
increased the viable cells to 0.28% or 1.21%, respectively, depending on the capsule used. Human 
IL-10 could not be measured in any of the samples. The results show that the enteric-coated 
capsules protected lactococci during passage through the upper gastro-intestinal tract. Therefore, 
enteric-coated capsules for ileal delivery of hIL-10 producing L. lactis can be a potential therapy for 
Crohn’s disease.  
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Introduction 
Ulcerative colitis and Crohn’s disease (CD) are inflammatory bowel diseases (IBD) caused by a 
disregulated immune response to antigens of the enteric bacterial microbiota in a genetically 
susceptible host (1-3). Treatment of IBD varies according to the type, distribution and severity of 
the disease. Although surgery is indicated in certain situations, drug therapy is the approach of 
choice to induce remission and thereafter prevent relapses. Drugs in the treatment of IBD can be 
used topically, orally or intravenously. Currently the drugs used are mesalazine-containing 
compounds, corticosteroids, immunomodulatory agents, antibiotics, and biological therapies (4,5).  
A new therapeutic approach under investigation is the inhibition of TH-1 polarization of the immune 
system by using the immunomodulatory recombinant human interleukin-10 (hIL-10)(5). IL-10 
controls and suppresses inflammation essentially by down regulating pro-inflammatory cytokine 
production. A number of studies with animal models of IBD have shown the efficacy of IL-10 for 
the regulation of mucosal inflammation (6,7). However, studies evaluating the therapeutic use of 
IL-10 in humans have yielded contradictory results.  
This may at least in part have resulted from insufficient delivery of the anti-inflammatory cytokine 
to the site of inflammation (8,9) and to the induction of interferon-γ following systemic 
administration (10). To overcome these obstacles, a new development is the targeted delivery of IL-
10 to the site of inflammation by means of in situ synthesis through recombinant vectors. This new 
approach may be safey and effective, as it avoids the complications and side effects associated with 
conventional therapies, resulting in an overall improvement of the quality of life of those affected 
by IBD. Steidler et al. (2000) tested this new approach of mucosal delivery of IL-10 using a 
recombinant Lactococcus lactis (L. lactis). Mouse models were used to show that the therapeutic 
dose of IL-10 can be reduced by localized delivery. In addition, daily ingestion of IL-10 secreting L. 
lactis caused a 50% reduction in colitis in mice treated with dextran sulphate sodium and prevented 
the onset of colitis in IL-10 knock-out mice. The therapeutic effect was due to mIL-10, synthesized 
de novo by IL-10-secreting L. lactis (7). 
For this therapy to be efficacious, an important criterion is the survival of the modified L. lactis 
strain in the gastrointestinal tract of the host (11,12). The environment in the gastrointestinal tract 
negatively influences the survival of lactic acid bacteria (13,14). This may be overcome by an 
enteric-coated formulation that protects the bacteria from gastric fluid and bile salts. Because of 
their active ileal reabsorption, the bile salt concentration is lower in the distal part of the small 
intestine (15). Therefore L. lactis should be targeted to the ileum in order to protect them from the 
detrimental bile salts. Besides, for the treatment of patients with CD localization in the terminal 
ileum, L. lactis should be targeted specifically to the site of inflammation (16). Based on the 
increasing pH along the GI tract, a pH dependent approach was used in the development of an 
enteric-coated capsule formulation containing freeze-dried, viable recombinant L. lactis for the ileal 
delivery of human IL-10 (17).  
The aim of the current study was to determine whether targeted delivery of hIL-10 producing L. 
lactis could be obtained by incorporating the strain in an enteric-coated capsule formulation. The 
effect of the formulation on survival and metabolic activity of the recombinant L. lactis was studied 
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in the TNO in vitro gastrointestinal model, which simulates to a high degree the successive dynamic 
conditions of the human stomach and small intestine (TIM-1)(13,18,19).  
Materials & Methods 
Strains 
The strains used were Lactococcus lactis subsp. cremoris MG1363 (20) and Lactococcus lactis 
Thy12. For the latter, the thymidilate synthase gene thyA of L. lactis MG1363 was replaced by the 
expression cassette for hIL-10. This thyA gene is essential for the growth of L. lactis as it plays an 
essential role in its DNA synthesis. The thyA- hIL-10+ L. lactis strain (L. lactis Thy12) produces 
hIL-10 (21) and when deprived of thymidine or thymine, its viability drops by several orders of 
magnitude, essentially preventing its accumulation in the environment (21). The strains were tested 
in the in vitro model as stationary phase grown cells or after incorporation in an enteric-coated 
formulation.  
Glycerol-stocks 
The strains were cultured in M17 (+0.5% glucose; Difco, Becton Dickinson, MD, USA) for 16 h at 
30°C. Thymidine (50 µg/mL; Sigma-Aldrich, Milwaukee, USA) was added to the broth for 
culturing L. lactis Thy12. After centrifugation of 10 mL of these cultures (~109 bacteria/mL), the 
pellets were resuspended into 10 mL BM9 (50 mM CO3-buffer at pH 8.5, supplemented with the 
M9 salts (7)). These bacterial suspensions were introduced in TIM-1. 
L. lactis formulation 
For the incorporation in an enteric-coated formulation, the L. lactis cultures were grown, harvested 
(centrifugation), and resuspended in 10% skim milk (Difco, Becton Dickinson, MD, USA) in order 
to obtain a cell concentration of ± 1010 CFU/mL. This suspension was subsequently freeze-dried. In 
order to perform visual analysis of disintegration of the enteric-coated capsules, carmin red (rubrum 
coccineum, Federa, Braine-l'Alleud, Belgium) was added to the freeze-dried powder before filling 
in ready-to-use enteric-coated HPMC capsules 00. The HPMC capsules (Capsugel, Bornem, 
Belgium) were coated with 7 mg/cm2 (~30µm) of either Eudragit® L30D-55 coating (Röhm, 
Darmstadt, Germany) dissolving at a pH 6.0 and higher, or Eudragit® FS 30 D (Röhm) dissolving at 
a pH equal or higher than pH 7.2 (22).  
The coated bodies were filled with 300 mg of freeze-dried powder (5*1010 CFU/capsule) and closed 
manually with the coated caps. After filling, the capsules were packed in aluminum sachets, sealed 
at 20% relative humidity and stored at -20°C until use in TIM-1.  
Survival and metabolic activity of L. lactis  
TIM-1  
Survival of the strains was studied in TIM-1 (Figure 5.1). Details of this computer-controlled 
system are given in Minekus et al. (23) and Marteau et al. (13). In short, the model consists of a 
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number of linked glass units with flexible walls inside. The intestinal content is mixed and moved 
by peristaltic movements, achieved by pumping water of 37°C around the flexible walls. During 
passage through the gastrointestinal tract, parameters such as temperature, pH, gastric and intestinal 
mixing, peristaltic movements, and gastrointestinal secretions are continuously monitored and 
controlled. The digested and dissolved low-molecular compounds are dialyzed continuously from 
the jejunal and ileal compartments of the model via hollow fiber membrane systems. Several studies 
have demonstrated the predictive value of this model in relation to survival of microorganisms 
(13,24) and oral drug delivery systems (19). 
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in 
dialysis 
lumen 
 
 
 
 
Strain introduction and passage 
In duplicate experiments the bacterial suspension or one capsule was mixed with 80 mL stomach 
water, 20 mL citrate buffer, and 100 mL water (23), and was introduced into the gastric 
compartment containing 10 mL gastric residue. The bacterial suspensions contained approximately 
1.0*1010 colony forming units (cfu) and the capsules approximately 5.0*1010 cfu of either L. lactis 
MG1363 or L. lactis Thy12. TIM-1 was programmed to simulate the adult gastrointestinal 
conditions after the intake of water (i.e., with a fast gastrointestinal passage)(19). The starting pH 
was 4.5, decreasing to 1.5 in 90 min. The gastric content was gradually delivered to the duodenum 
over a period of 3 h, according to data obtained from clinical studies (23). In the duodenal 
compartment the gastric content was neutralized to pH 6.5 ± 0.2, and bile and pancreatin were 
secreted continuously. The content of the duodenum (residence time approx. 10-15 minutes) was 
Figure 5.1 Schematic diagram of the 
dynamic in vitro gastrointestinal 
model (TIM-1): A. gastric 
compartment; B. pyloric sphincter; 
C. duodenal compartment;  
D. peristaltic valve; E. jejunal 
compartment; F. peristaltic valve; 
G. ileal compartment; H. ileo-caecal 
valve; I. pH electrodes; J. gastric 
secretion bottles with acid and 
enzymes; K. duodenal secretion 
bottles with bile, pancreatin, 
bicarbonate; L. secretion of 
bicarbonate to control the intestinal 
pH; M. pre-filter system; N. hollow 
fiber semi-permeable membrane 
system; O. water absorption system;  
P. closed dialyzing system.  
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delivered into the jejunal compartment (pH 6.8) and after that into the ileal compartment (pH 7.2), 
according to the physiological intestinal transit after the intake of water by a human adult. It was 
assumed that the enteric-coated capsules would not disintegrate in the stomach. As the enteric-
coated capsules were not able to pass the pyloric valve in the model (because of their size), they 
were transferred manually after 1 h from the stomach to the duodenal compartment in a simulated 
housekeeper wave. This had the additional advantage that passage from the stomach to the small 
intestine was standardized. If an enteric-coated capsule did not disintegrate in the duodenum, or the 
jejunum, it was again transferred manually after 1 h to the jejunum or the ileum, respectively. The 
survival experiments lasted 5 h, only for the Eudragit® FS 30 D coated capsules filled with L. lactis 
Thy12 also a 6 h experiment was performed.  
Sampling 
At the end of the ileal compartment, the simulated ‘ileo-caecal valve’ (Figure 5.1H) delivered the 
intestinal contents into a sampling bottle at 4-8°C (ileal effluent). Every 60 minutes during 5 h (or 6 
h) the total collected volume was measured and analyzed for viable microorganisms per mL. Also 
the cfu per mL at time zero was determined in the ‘meal’ before introduction of the test-product in 
the gastric compartment. This meant for the capsules, that the initial numbers of bacteria had to be 
determined in separate capsules. Furthermore, all three residues of the model from respectively 
stomach and duodenum, jejunum, and ileum were collected at the end of an experiment and 
analyzed for viable counts. Results were expressed as percentage of the initial intake. 
The same ileal effluent samples as mentioned above were also used for analyzing the amount of 
hIL-10. The Eudragit® L30D-55 coated capsules disintegrated in the jejunum (see results). In this 
case additional luminal samples from the jejunum (t=3, 4, and 5 h) were also analyzed for the 
amount of hIL-10.  
Determination of viable counts and hIL-10 
For viable cell count determinations, the samples were diluted (10-fold serial dilution) in pepton-
physiological salt and plated on M17 agar (+0.5% glucose; Difco and +50 µg/mL thymidine in case 
of L. lactis Thy12; Sigma-Aldrich). 
The concentration hIL-10 in each sample was determined in a sandwich ELISA. Maxisorp F96 
plates (Nunc, Roskilde, Denmark) were coated with 2 µg/mL rat anti-human IL-10 (BD Biosciences 
Pharmingen, San Diego, CA, USA). The plates were blocked with a 0.1% casein solution. A 2-fold 
dilution series of hIL-10, starting from 1 ng/mL and appropriate dilutions of the samples were 
loaded on the plates. Between each step the plates were washed with PBS + 0.05% Tween-20. The 
bound hIL-10 was detected with 1/1000 diluted biotinylated rat anti-human IL-10 combined with 
horseradish peroxidase coupled streptavidine. The plates were developed with TMB substrate (all 
from BD Biosciences Pharmingen). The reaction was stopped after 30 min with 1M H2SO4. The 
absorbance was measured at 450 nm.  
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Results 
Survival  
For the survival no distinction was seen between L. lactis MG1363 and L. lactis Thy12. Therefore, 
the average cumulative survival out of 4 TIM-1 experiments with stationary phase grown cells is 
shown in Figure 5.2A. Especially in the first 120 minutes after the intake, bacteria survived the 
passage through the gastro-small intestinal tract. More than half of the bacteria that survived 
passage were still in the model as residue after 300 minutes of running. Viable cells could only be 
detected in the residue of the jejunum and not in the residue of the stomach and duodenum. At the 
end of the experiment, 0.04% of the ingested stationary phase grown cells (~8.5*106 cells) had 
passed the gastric and small intestinal compartments alive and was recovered in the ileal effluent 
and -residue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Cumulative survival of lactococci in time (min) as % of the intake (left axis, ileal delivery = 
white bars and residue = black bars) and absolute (right axis, line). A) stationary phase grown cells; B) 
Eudragit® L30D-55 coated capsules. For comparison the scales of the y-axes has been kept the same in A) 
and B).
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Incorporation of L. lactis MG1363 and L. lactis Thy12 in Eudragit® L30D-55 coated capsules, 
designed to disintegrate in the proximal small bowel, increased survival (Figure 5.2B). The 
Eudragit® L30D-55 coated capsules showed no disintegration in the stomach or duodenal 
compartment. The disintegration started immediately in the jejunum compartment (visual analysis; 
release of carmin red from the coated capsuels). About 50% of the volume of the capsule had 
disappeared at 150 min after intake and the capsules showed complete disintegration at 175 min 
after intake. With a cumulative survival of 0.28% of the intake (~2.4*108 cells), the increase in 
survival for these encapsulated strains compared to stationary phase grown cells was almost 8-fold. 
The bacteria were also more gradually delivered to the colon by incorporating them in an enteric-
coated capsule before ingestion. Also here, more than half of the cells that survived passage still 
resided in the model after termination of the experiment, and viable cells were only detected in the 
residue of the jejunum and ileum.  
The Eudragit® FS 30 D coated capsules, designed to disintegrate in the distal small bowel, passed 
the stomach and small intestine compartments intact. It was observed that the coated capsules 
became swollen and sticky, and that the pink color (carmin red) of the capsule content became more 
intense towards the distal region, probably indicating an increased permeability. Between 240 and 
300 minutes after intake, the release of L. lactis started. At this time, the capsule had been in the 
ileal compartment for one hour (180-240 minutes; pH 7.2). The final cumulative survival of the 
released lactococci was 0.17% of the intake (sum of ileal effluent and ileal residue; average for both 
L. lactis MG1363 and L. lactis Thy12). The remaining capsules still contained on average 8.44% of 
the initial amount of lactococci in these capsules (see Table 5.1). 
Table 5.1. Cumulative survival of lactococci in a Eudragit® FS 30 D capsule, in % of the intake and in 
absolute numbers (cells), during a 5 h experiments and a 6 h experiment.  
Survival during a 5 h experiment Survival during a 6 h experiment Eudragit®  
FS 30 D % of intake absolute numbers (cells) % of intake absolute numbers (cells) 
Ileal delivery 0.17 4.6*107 0.25 3.1*108 
Residue 0.0001 1.3*105 0.96 8.6*108 
Capsule 8.44 6.4*109  -  -  
Total 8.61 6.4*109 1.21 1.2*109 
 
The TIM-1 experiments were repeated (n=2; Eudragit® FS 30 D capsules, only with L. lactis 
Thy12) to study the effect of one extra hour residence time in the ileal compartment (time of 
experiment=6 h). In this experiment, the capsules totally disintegrated between 300 and 360 
minutes, as a result of the combination of pH and peristaltic forces. The total cumulative survival of 
the lactococci was 1.21% of the intake. Also in this case, after total disintegration of the coated 
capsules, more than half of the cells that survived passage were still in the model as ileal residue 
after the 6 h (see Table 5.1). 
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Finally, a static incubation was performed to study the effect of the ileal contents (e.g. bile) on 
survival of L. lactis Thy12. One Eudragit® FS 30 D coated capsule was incubated for 5 h in a 
mixture of bile, pancreatic juice, and ileal dialysate, resembling the ileal lumen in TIM-1. The pH 
was set at 7.2 and the incubation occurred in a shaking water-bath of 37°C. Another Eudragit® FS 
30 D capsule was first opened and the content was then mixed with the ileal fluid. From Figure 5.3 
it can be concluded that after 300 minutes the presence of viable bacteria in both static incubations 
was more or less the same. After 60 minutes the release of L. lactis Thy12 from the coated capsule 
started, although visual analysis indicated that the disintegration occurred between 120 and 180 
minutes. At 180 minutes, the survival (and/or releases in case of the coated capsule incubation) 
stabilized in both types of static incubations. These experiments corroborate that survival of L. 
lactis in intestinal fluids is very low. Under these conditions survival as percentage of the initial 
amount of cells varied from 0.06% (deliberately opened capsule) to 0.25% (intact capsule). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Release and/or survival of L. lactis Thy12 cells out of Eudragit® FS 30 D capsules during a static 
incubation of 5 h.   intact capsule    deliberately opened capsule 
hIL-10 analysis 
Human IL-10 was only detected in samples of the log-phase grown cells of L. lactis Thy12, taken 
from the mixture with artificial saliva and water before introduction in the gastric compartment. 
One mL of bacterial suspension of L. lactis Thy12 contained 641 pg hIL-10. Human IL-10 could 
not be measured in any of the ileal effluent or jejunum samples.  
Discussion 
A new therapeutic approach for CD is the targeted delivery of hIL-10 to the ileum by a recombinant 
L. lactis strain. For this therapy to be efficacious, an important criterion is the survival of L. lactis in 
the gastrointestinal tract. This implies the development of an enteric-coated formulation that 
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protects the bacteria from gastric fluid and, amongst others, bile salts and releases the bacteria at the 
site of inflammation.  
In this study two types of enteric-coated capsules were evaluated for ileal delivery of hIL-10 
producing L. lactis. This was studied in TIM-1, an in vitro gastrointestinal model simulating to a 
high degree the successive dynamic processes in the stomach and the small intestine (13,23). The 
study clearly indicates that both types of capsules are effective in protecting lactococci during 
passage through the stomach and (parts of) the small intestine.  
Only 0.04% (yet still representing 8.5*106 cells) of the stationary-phase grown lactococci cells was 
recovered after oral intake. This has been observed previously for passage of unprotected lactocci 
and other lactic acid bacteria through the small intestine (14,19,24,25). Vesa et al. (2000) reported 
an ileal survival for L. lactis MG 1363 of 1.0 % of the intake. This higher survival as compared to 
our findings with the lactococci as stationary phase grown cells is most likely the result of the use of 
milk instead of water as meal matrix in the human volunteer study; whereby milk acts as a 
protecting (e.g. buffering) matrix. 
Incorporating L. lactis MG1363 and L. lactis Thy12 in Eudragit® L30D-55 coated capsules 
increased the viable bacteria to 0.28%. Eudragit® FS 30 D coated capsules improved this even 
further, up to 1.21% and 8.61% of the total intake could be recovered, depending on the incubation 
time in the ileal fluid (6 h, leading to complete disintegration of the capsules, and  
5 h, where the capsules were still largely intact, respectively).  
This general protecting property is underscored also in studies in pigs, albeit with different efficacy, 
where the in vivo situation shows even higher, nearly complete recovery of the inoculum ((21) and 
unpublished data). A major difference in the both study designs was the site of ‘ingestion’. In our in 
vitro study the capsules were introduced in the stomach. In the pig study the capsules were inserted 
through a duodenal fistula (pH duodenum 6.2). In addition, the higher recovery in the pigs can be 
due to the intrinsic differences between the in vivo and in vitro situation, where the latter for 
instance does not possess of a mucus layer that may protect the bacteria.  
An advantage of the use of in vitro systems such as TIM-1 is the fact that time-samples can be 
taken, combined with the ability to visualize disintegration. Disintegration of the Eudragit® L30D-
55 coated capsules started immediately in the jejunum (pH 6.8), and disintegration was completed 
in about 55 minutes. Therefore, the cells were in contact with the jejunal and/or ileal contents for a 
minimum period of 125 minutes and a maximum period of 180 minutes, and in this situation the 
average total cumulative survival was 0.28% (representing 2.4*108 cells). From the static 
incubations with the unprotected cells (deliberately opened capsules) it can be concluded that the 
survival in ileal contents decreased from 0.31% (120 min of incubation) to 0.06% of the initial 
intake (180 min of incubation). By comparing the percentages of survival from both type of 
experiments, it can be concluded that the Eudragit® L30D-55 coated capsules seems to protect the 
lactococci for a period of approximately 175 minutes, thereby increasing survival 8-fold. 
In the TIM-1 experiments that lasted 5 h no visual disintegration of the Eudragit® FS 30 D coated 
capsules was observed, and viable count analysis showed a release of L. lactis in the ileal fluid of 
0.17% of the intake (4.6*107 cells). The capsules had been in the ileal compartment for 120 minutes 
and still contained 8.44% of the initial amount of viable cells (6.4*109 cells). In the TIM-1 
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experiments that lasted 6 h, the capsules had been in the ileal compartment for 180 minutes, and 
were completely disintegrated. Total cumulative survival was 1.21% (1.2*109 cells), which is 34-
fold higher than the stationary phase, unprotected cells. Furthermore, a static incubation was done 
with this type of capsule. After 60 minutes, the release of L. lactis Thy12 started (Figure 5.3), 
although visual analysis indicated that the disintegration occurred between 120 and 180 minutes. At 
180 minutes, the cumulative survival was 0.09% of the initial amount of cells. For the Eudragit® FS 
30 D coated capsules a retention time of at least 60 minutes in an environment resembling the 
human ileum is necessary for the release of the lactococci. Compared to the Eudragit® L30D-55 
coated capsules, the Eudragit® FS 30 D coated capsules are more effective in protecting lactococci 
during passage through the stomach and the small intestine (0.28% versus 1.21% survival). 
Depending of the site of action, the proper capsule can be chosen. If the site of action should be the 
jejunum, a Eudragit® L30D-55 coated capsule is the preferred choice of drug dosage form; if the 
site of action is the ileum or proximal colon, a Eudragit® FS 30 D coated capsule should be chosen. 
In conclusion, our results show that the enteric-coated capsules protect lactococci during passage 
through the upper gastrointestinal tract. The choice for one type of formulation, Eudragit® L30D-55 
or Eudragit® FS 30 D, depends on the patients’s CD localization and ileal pH. The bacterium’s 
capacity to secrete hIL-10 was validated in vivo in pigs (21), but was not seen in our in vitro 
systems. The absolute amount of viable Thy12 bacteria that would have been able to produce hIL-
10 in vitro varied from 8.5*106 to 1.2*109 cells. In vivo 4.2*1010 and 4.4*1011 Thy12 cells were 
detected in the lumen and in intestinal tissue, respectively. These lower amounts of viable cells in 
vitro go together with hIL-10 concentrations (~0.5 – 5.0 pg/mL) that are below the detection limit 
of the ELISA assay used.  
Even though survival of L. lactis is low when expressed in percentages, total viable cell numbers at 
the end of the small intestine reach 2.4*108 – 1.2*109. Enteric-coated capsules for ileal delivery of 
hIL-10 producing L. lactis can be a potential therapy for Crohn’s disease. Combining these results 
with the outcome of a preclinical study in which the same two formulations with hIL-10 producing 
L. lactis has been administered to 10 patients suffering from CD (Amsterdam Medical Centrum, 
The Netherlands) will provide valuable insight into safety, biological containment and clinical 
effectiveness of this novel medical strategy. 
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Abstract 
We aimed to determine whether anti-TNF-α monoclonal antibody therapy for Crohn’s disease (CD) 
has an effect on the composition of the faecal microbiota in these patients. It was hypothesized that 
if the microbial composition correlates with clinical disease activity, microbial metabolites possibly 
do as well, given their relationship with the microbial composition. Therefore, the second aim of 
this study was to investigate the possible use of microbial metabolites as markers for disease 
activity in inflammatory bowel disease (IBD).  
The study population consisted of 23 subjects divided over three groups: healthy individuals, IBD 
patients in remission and patients with active CD. The latter patients were studied twice: 
immediately before and two weeks after a single, first infusion of infliximab (the anti-TNF-α 
antibody). Microbial composition was determined using the classical plating technique and FISH, 
and the following potential disease activity markers were determined in the faecal samples: dry 
matter, pH, short-chain fatty acid, branched-chain fatty acids, and lactate. 
Infliximab therapy led to an increase of the density of the bacterial population, to a decrease of the 
faecal L- versus D-lactate ratio, and in three of the four patients this therapy led to an increase of 
faecal dry matter. By comparing the patients with active CD with the healthy controls and the IBD 
patients in remission, an increase in total number of faecal bacteria and in faecal dry matter, and a 
decrease in the faecal L- versus D-lactate ratio seem to correlate overall with a lower severity of 
disease activity, and thus with health status. These three parameters can possibly be used as clinical 
disease activity markers, as opposed to the absolute excretions of microbial metabolites, given the 
complex interaction between production, absorption/utilization and excretion.  
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Introduction 
The gastrointestinal microbiota plays a role in Crohn’s disease (CD) and ulcerative colitis (UC). 
Evidence for this role includes responses to antimicrobial therapy, infiltration of inflammatory 
bacterial products across the intestinal mucosal barrier, host immunity against (or rather loss of 
tolerance to) bacteria indigenous to the large intestine, and the role of bacteria in disease 
development in animal models of inflammatory bowel disease (IBD). Specific microorganisms (1-
5) and their metabolites (6,7) have both be hypothesized to be mediators of injury and 
inflammation. 
If (specific) microorganisms cause or maintain inflammation, the composition of the microbiota 
from IBD patients may be different from that of healthy individuals. However, reports on this are 
conflicting (3,8-10). Most data on the involvement of microbiota in IBD have been obtained using 
classical plating and speciation techniques. These techniques are limited by the fact that a major 
proportion of the microbiota, estimates range between 12 and 60%, can not be cultured (11,12). A 
molecular approach towards microbiota analysis by means of denaturing gradient gel 
electrophoresis (DGGE), fluorescent in situ hybridisation (FISH), or DNA-arrays (DNA-chips), 
may provide better insight in the composition of the faecal microbiota in IBD patients. 
The large interindividual variation in the microbial composition in human subjects makes it difficult 
to conclude if a microbiota is ‘normal’ or ‘abnormal’. Furthermore, in severe extensive IBD an 
abnormal composition of the gut microbiota may be a result, rather than a cause of the disease. For 
instance, abnormal gut transit times, the presence of blood, mucus, and shedded epithelial cells, as 
well as the treatment of IBD patients with antimicrobials or other drugs can result in a microbiota 
that is different in composition from that from healthy individuals (8,13,14). The determination 
whether patients with IBD show evidence of an ‘abnormal’ composition of the microbiota in their 
large intestine and whether this is related to the initiation or exacerbation of the disease is thus a 
difficult, but important issue to solve. An improvement in the composition of the microbial 
community may relate to an improved clinical outcome. 
The proinflammatory cytokine tumor necrosis factor (TNF)-α has been demonstrated to play a 
crucial role in the pathogenesis of CD. An increased TH-1 response is detected in CD; these cells 
mediate cellular immunity and macrophage activation. Activated macrophages produce 
proinflammatory cytokines, including TNF-α (15-17). Genetically engineered monoclonal 
antibodies, specifically directed against TNF-α and given intravenously, have been shown to have a 
dramatic and sustained effect in inducing remission in IBD patients (18-20). The exact mechanism 
of anti-TNF-α monoclonal antibodies, apart from direct activity that neutralizes both soluble and 
transmembrane TNF-α, is not fully understood. The proposed mechanisms include inhibition of 
binding of TNF-α with its receptors, as well as lysis of TNF producing cells via complement 
fixation, antibody dependent cytotoxicity, and an increased susceptibility to apoptosis of intestinal 
mucosal T cells (21,22). 
Our aim was to determine whether anti-TNF-α monoclonal antibody therapy for CD has an effect 
on the composition of the faecal microbiota in these patients. It was hypothesized that if the 
microbial composition correlates with clinical disease activity, microbial metabolites possibly do as 
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well, given their relationship with the microbial composition. Therefore, the second aim was to 
investigate the possible use of microbial metabolites as markers for disease activity in IBD. 
Materials and Methods 
Study population 
The study population consisted of 23 subjects divided over three groups: (1) the CD-active group 
consisting of four patients (CD1-4) with mild-to-moderately active CD with a Clinical Disease 
Activity Index (CDAI) ranging between 107 and 265, (2) the IBD-remission group consisting of 12 
IBD patients in remission, and (3) the control group consisting of 7 healthy subjects. The patients in 
the CD-active group were studied twice, immediately before and two weeks after a single, first 
infusion of infliximab (5 mg/kg; Remicade®, Centocor Inc, Horsham, USA). The subjects in the 
other two groups were studied only once. The IBD-remission group consisted of 7 patients with CD 
affecting the colon and 5 patients with UC. Two CD patients from the IBD-remission group and all 
seven healthy subjects had not taken any medication in the 6 months prior to the study. The other 
patients were treated with mesalazine (n=5), corticosteroids (n=3), or immunomodulatory agents 
(n=3). Clinical response of the CD-active patients was defined as a reduction of 70 or more points 
in the score on CDAI or a CDAI score below 150 (=remission). C-reactive protein (CRP) values 
were also determined to score disease activity.  
Faecal Analysis 
Fresh faecal material from each subject was collected and frozen at -80˚C until analysis. 
Microbial composition 
Microbial composition was determined using the classical plating technique and FISH. Plating was 
performed as described before (23). For FISH, weighed portions (about 0.5 g) of each stool were 
fixed with 3% paraformaldehyde in PBS (per liter 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, 
and 0.24 g of KH2PO4) as described previously (24). Samples were applied to glass slides following 
a protocol described previously (25), except that the dilution of the paraformaldehyde fixed fecal 
samples was made in PBS and not in 5% Tween solution. The slides were hybridized with the 
probes listed in Table 6.1 or stained with 4’, 6’-diamidino-2-phenylindole (DAPI) as described 
(24,25). Fluorescent cells in the samples were counted automatically (25) with a Leica DMRXA 
epifluorescence microscope (Leica, Wetzlar, Germany) or visually with an Olympus BH2 
epifluorescence microscope (in case of numbers below 4 * 108 cells/g or inhomogeneous spreading 
of the cells). 
Potential faecal disease activity markers 
The following potential disease activity markers were determined in the faecal samples: dry matter, 
pH, short-chain fatty acid (SCFA), branched-chain fatty acids (BCFA), and lactate. The dry matter 
(expressed as percentage of a wet weight sample) was determined by drying approximately 1 g of a 
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faecal sample in a pre-weighed tube in an incubator of 100°C until no loss of weight could be 
detected. Both SCFA, BCFA, and lactate concentrations were measured as described before (26). 
Potential disease activity markers were expressed as unit per gram faeces (wet weight).  
Table 6.1 Stain or probes used to determine the microbial composition of faeces by FISH. 
Target group Stain or probe References 
Total cells DAPI (24) 
Bacteroides/ Prevotella Bac303 (27) 
Eubacterium rectale/ Clostridium coccoides-
group (Clostridium group XIVa) 
Erec482 (24) 
Bifidobacterium Bif164 (28) 
Eubacterium lowG+C #2  
(Faecalibacterium sp.) 
Elgc01 (24,29) 
Atopobium group Ato291 (30) 
Clostridium ramosum/ Clostridium spiroforme/ 
Clostridium cocleatum group 
Cspiro222, differentiated on bases of morphology:  
C. ramosum straight rod, others curved or coiled up 
rods 
(31) 
Clostridium histolyticum/ Clostridium 
lituseburense group (Clostridium group I,II and 
XI) 
Chis150/Clit135 (24) 
Lactobacillus/ Enterococcus Lab158 (32) 
Streptococcus/ Lactococcus Strc493 (24) 
 
Statistical Analysis 
Results for each group are expressed as means ± SEM, except for FISH. There, the median and the 
range for the groups are shown. All statistical analyses were conducted using the Statistical Package 
for the Social Sciences (SPSS) for Windows version 12.0. Descriptive statistics were used to 
analyse and report the data. Differences in outcome between groups were calculated by means of 
the Mann-Whitney test. Differences within the CD-active group over time (before versus after 
treatment) were performed using Wilcoxon’s signed ranks test. A p≤0.05 was considered 
significant. 
For FISH, results of one IBD-remission subject were not included because of poor hybridization.  
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Results 
Clinical disease activity markers 
The patients on anti-TNF-α therapy all showed a reduction in the CDAI score two weeks after the 
single infliximab infusion (Figure 6.1). Infliximab treatment in patient CD1 caused serious side 
effects, resulting in an increase in CRP from 59 to 223 mg/dL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 CRP (closed symbols) and CDAI (open symbols) scores of patients CD1 (■, □), CD2 (♦, ◊), 
CD3 (▲, ∆ ) and CD4 (●, ○) before and after anti-TNF-α treatment. 
Microbial composition 
Colony forming units (CFU) by plating 
Total bacterial counts as determined by plating were significantly lower in the CD-active patients 
than in the healthy controls and IBD-remission group (p=0.01 and 0.05, respectively; Table 6.2). 
There was no difference in total bacterial counts between the healthy controls and IBD patients in 
remission, but that of the CD-active patients after treatment was still significant lower than that of 
the healthy volunteers (p=0.02). Infliximab therapy led to an increase in total bacterial counts in the 
CD-active group. This increase was of borderline significance (p=0.07) and observed in each 
individual in this group. Bifidobacteria, bacteroides, lactobacilli, and sulphite reducing clostridia 
were the bacterial genera that all showed increases in counts, except in patient CD4 where the 
bifidobacteria and bacteroides remained stable upon treatment. The colonization density of 
enterobacteriaceae and enterococci was already before infliximab therapy similar in the CD-active 
group to both other groups. The bacterial composition of faeces did not differ between the IBD-
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remission and healthy control group, except for a significantly higher number of lactobacilli in 
faeces of healthy subjects (p=0.01).  
Table 6.2 Microbial composition as determined by plating; log10 CFU/gram faeces (mean ± SEM for 
healthy controls, IBD-remission, CD-before and CD-after (sub)groups; individual data for the CD-active 
group). 
CD-active 
(n=4) 
CD1 
 
CD2 
 
CD3 CD4 Bacteria 
 
Healthy 
controls 
(n=7) 
IBD-
remission 
(n=12) before after before after before after before after before after 
bifidobacteria 8.7 
(0.2) 
8.8** 
(0.2) 
7.2* 
(0.5) 
7.7 
(0.5) 
6.9 7.8 5.6 7.1 7.7 8.1 6.0 6.0 
bacteroides 9.3 
(0.3)  
9.3** 
(0.3) 
7.9* 
(0.4) 
8.2# 
(0.4) 
8.0 8.2 6.5 7.2 8.3 8.6 7.1 7.1 
lactobacilli 8.7† 
(0.6)  
4.8 
(0.4) 
3.9* 
(0.7) 
4.9# 
(0.5) 
1.5 5.0 2.6 2.9 4.2 4.9 4.2 5.1 
enterococci 6.2 
(0.2) 
6.5 
(0.4) 
6.9 
(0.8) 
6.4 
(0.5) 
5.0 5.2 3.9 4.8 7.6 6.2 5.5 7.0 
entero-
bacteriaceae 
6.7 
(0.4) 
7.5 
(0.5) 
7.1 
(0.6) 
7.3 
(0.7) 
7.6 7.4 5.1 4.6 6.0 7.8 5.4 5.9 
sulphite 
reducing 
clostridia 
7.2 
(0.4) 
6.7** 
(0.3) 
4.3* 
(0.7) 
6.5 
(0.7) 
3.9 7.1 1.6 4.2 4.7 6.1 4.2 4.6 
total counts 9.5 
(0.2) 
9.4** 
(0.3) 
8.0* 
(0.4) 
8.4# 
(0.4) 
8.2 8.4 6.6 7.5 8.5 8.8 7.2 7.4 
† p≤0.05 healthy controls versus IBD-remission  * p≤0.05 healthy controls versus CD-before 
# p≤0.05 healthy controls versus CD-after  ** p≤0.05 IBD-remission versus CD-before 
before/after=before/after infliximab treatment 
FISH 
The relative proportions of the various bacterial target groups were determined by correlating the 
respective cell counts with the total bacterial counts detected with DAPI staining. Bacteria detected 
with DAPI staining, but not with any of the specific probes, are hereafter referred to as unidentified 
bacteria.  
The DAPI stained cell counts of the four CD-active patients before treatment (median: log 9.5, 
range: log 9.3-10.1 CFU/gram) increased after infliximab treatment to log 10.5 (median; range: log 
10.0-10.6 CFU/gram; p=0.07). This increase was seen in all CD-active patients and thus matched 
the plating results. Before treatment, the total counts for the CD-active patients were also 
significantly lower than those of both the healthy controls and the IBD-remission groups (p=0.01 
for both). There were no significant differences in total counts between the CD-active patients after 
treatment, the healthy controls (median: log 10.9, range: log 10.2-11.0 CFU/gram), and the IBD 
patients in remission (median: log 10.4, range: log 10.0-10.9 CFU/gram). That between the latter 
two groups was of borderline significance (p=0.09). 
No significant effects of anti-TNF-α antibody treatment on the relative composition of faecal 
microbiota of the CD-active patients were observed (Table 6.3, results are expressed as % of total 
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bacteria). Furthermore, no significant compositional differences between the healthy controls and 
the IBD patients in remission did appear. The composition of the CD-active patients differed from 
both other groups with respect to a (significant) higher proportion of the Bacteroides/Prevotella 
group (for significancy: see Table 6.3).  
Table 6.3 Composition of the faecal microbiota of healthy controls, IBD patients in remission, and patients 
with active CD before and after infliximab treatment detected with FISH. Counts are expressed as % of total 
bacteria detected with DAPI staining (median and range for healthy controls, IBD-remission, CD-before, and 
CD-after (sub)groups; individual data for the CD-active group).  
CD-active 
(n=4) 
CD1 
 
CD2 
 
CD3 CD4 
 
group Healthy 
controls 
(n=7) 
IBD 
remission 
(n=11) before after before after before after before after before after 
Bacteroides/ 
Prevotella 
group 
6.7 
(3.4-26.1) 
6.9‡ 
(0.4-21.7)  
17.5** 
(12.3-53.2) 
29.9# 
(12.7-34.6) 
16.1 28.0 18.9 31.9 53.2 12.7 12.3 34.6 
Eubacterium 
rectale/ 
C. coccoides 
group 
14.6 
(6.0-45.8) 
22.6 
(1.7-50.2) 
24.2 
(6.7-45.5) 
18.9 
(15.6-35.2) 
6.7 15.6 22.0 35.2 26.4 18.2 45.5 19.5 
Bifidobacterium 4.2 
(0.7-6.3) 
1.8 
(0.4-11.1) 
3.7 
(1.4-7.9) 
1.7 
(0.7-12.4) 
1.4 1.3 2.3 2.2 5.0 12.4 7.9 0.7 
low G+C 
Gram-positive 
bacteria 
8.8 
(0.3-12.6) 
5.3 
(0.4-12.2) 
2.6 
(0.1-23.9) 
3.8 
(0.8-11.9) 
4.9 6.1 0.4 1.5 23.9 11.9 0.1 0.8 
Atopobium 
group 
2.9 
(0.1-7.5) 
3.5 
(1.4-7.2) 
0.9 
(0.2-4.3) 
0.4 
(<0.1-4.9) 
1.1 0.4 4.3 4.9 0.2 0.2 0.8 <0.1 
C. ramosum  0.6 
(0.2-1.8) 
0.6 
(0.0-4.2) 
0.9 
(<0.5-2.9) 
0.8 
(0.2-1.5) 
<0.5 0.2 0.5 0.7 2.9 1.5 1.0 1.0 
C. spiroforme/ 
C. cocleatum 
0.1 
(0.0-0.2) 
0.2 
(0.1-0.4) 
0.1 
(<0.1-0.3) 
0.1 
(<0.1-0.3) 
<0.5 0.1 <0.1 0.1 0.3 0.3 0.1 <0.1 
C. histolyticum/ 
C. lituseburense 
group 
0.2 
(0.1-0.2) 
0.2 
(0.0-0.1) 
0.2 
(0.2-0.6) 
0.1 
(<0.1-0.6) 
<0.5 <0.1 0.2 0.1 0.2 0.1 0.6 0.6 
Lactobacillus/ 
Enterococcus 
0.0 
(0.0-0.1) 
0.1 
(0.0-0.1) 
0.02 
(<0.1-0.5) 
0.05 
(<0.1-0.1) 
<0.5 <0.1 <0.1 0.1 <0.5 <0.1 <0.5 <0.1 
Streptococcus/ 
Lactococcus 
1.1 
(0.3-1.8) 
0.3 
(0.1-0.4) 
0.5 
(0.2-3.1) 
1.1 
(0.2-2.5) 
0.4 0.3 0.6 1.7 0.2 0.5 3.1 2.5 
unidentified 
bacteria 
57.6 
(23.9-79.0) 
50.8 
(30.7-87.6) 
39.8 
(0-69.4) 
41.2 
(21.6-48.1) 
69.4 48.1 50.9 21.6  - 42.3 28.8 40.0 
# p≤0.05 healthy controls versus CD-after  ** p≤0.05 IBD-remission versus CD-before 
‡ p≤0.05 IBD-remission versus CD-after   before/after=before/after infliximab treatment 
Two other trends could be detected. The lower severity of disease, the higher the percentages of 
both low G+C Gram-positive bacteria and unidentified bacteria. So, percentages were on average 
increasing in the CD-active patients upon infliximab therapy, were even higher for the IBD-
remission group, and were highest for the healthy controls. But these trends were not detected for 
all individual CD-active patients. 
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Potential faecal disease activity markers 
Dry matter and pH 
The average faecal dry matter in the CD-active group was 11.0 ± 2.3% before and 17.3 ± 2.1% after 
treatment. This increase was not significant but was seen in three out of the four CD-active patients. 
Patient CD3 had the lowest improvement in CDAI score, but showed a remarkable increase in 
faecal dry matter: from 4% before treatment to 23% after treatment (Table 6.4).  
Faecal dry matter was significantly higher in healthy subjects than in IBD patients, both those in 
remission and those with active disease before and after anti-TNF-α treatment (p≤0.02 for all). Also 
the difference between the IBD-remission group and the CD-active patient before treatment was 
significant (p=0.04). 
Faecal pH did not vary significantly between groups; overall faecal pH ranged from 5.3 to 7.2. 
Metabolites 
The total lactate and SCFA concentrations in faeces showed large interindividual differences.  
The total lactate concentrations did not differ between groups. In the CD-active group, infliximab 
treatment had no significant effect on lactate concentrations, but it did change the ratio of L- versus 
D-lactate (L:D lactate ratio) from 1:0.5 to 1:1.3 (p=0.07). This shift in favor of D-lactate was seen 
in every individual CD-active patient. The L:D ratio was 1:1.6 for the IBD-remission group and 
1:2.9 for the healthy subjects (p≤ 0.04 for healthy controls versus IBD-remission, healthy controls 
versus CD-active both before and after treatment, and for IBD-remission versus the CD-active 
patients before and after treatment).  
Although no significant differences concerning faecal SCFA or BCFA excretion were observed 
when comparing the CD-active patients before and after treatment, all excretions (except for iso-
butyrate) were higher after the infliximab infusion. On the other hand, the excretions of all 
individual SCFA and BCFA were lower in faeces of the healthy control group compared to the 
IBD-remission group (Table 6.4). For acetate and the total SCFA plus BCFA excretion these 
differences were significant (p=0.02 and 0.04, respectively). All other significant differences 
between the different study (sub)groups did not correlate with health status (see Table 6.4). 
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Table 6.4 Potential faecal disease activity markers per gram faeces (wet weight). Dry matter: %; lactate and 
SCFA: µmol (mean ± SEM for healthy controls, IBD-remission, CD-before and CD-active (sub)groups; 
individual data for the CD-active group). 
CD-active 
(n=4) 
CD1 
 
CD2 
 
CD3 CD4 potential 
faecal  
disease 
marker 
Healthy 
controls 
(n=7) 
IBD-
remission 
(n=12) before after before after before after before after before after 
pH 6.2 
(0.1) 
6.3 
(0.1) 
6.1 
(0.4) 
5.9 
(0.1) 
5.8 5.9 5.3 5.9 7.2 6.2 6.0 5.8 
dry matter 30.2† 
(2.0) 
21.2** 
(2.3) 
11.0* 
(2.3) 
17.3# 
(2.1) 
12.0 14.7 12.9 17.9 4.4 22.9 14.7 13.7 
L-lactate  4.0 
(1.3) 
9.6 
(3.7) 
13.6 
(10.2) 
9.1 
(2.4) 
43.9 13.9 1.4 4.8 2.3 12.6 6.8 5.2 
D-lactate 10.1 
(2.6) 
16.7 
(5.6) 
4.0 
(2.4) 
11.8 
(3.1) 
11.1 17.4 0.8 6.3 2.1 16.9 2.0 6.6 
total 
lactate 
14.1 
(3.6) 
26.3 
(9.3) 
17.6 
(12.5) 
21.0 
(5.5) 
54.9 31.3 2.2 11.1 4.4 29.5 8.8 11.8 
acetate 21.3† 
(5.0) 
55.0 
(9.9) 
34.5 
(18.9) 
59.7# 
(8.7) 
14.8 83.7 89.1 50.4 4.7 60.5 29.5 44.1 
propionate 9.3 
(1.6) 
16.7 
(3.4) 
7.0 
(3.6) 
18.9# 
(3.3) 
5.1 27.0 17.6 21.4 1.5 12.3 3.6 14.7 
iso-
butyrate  
1.4 
(0.2) 
2.0** 
(0.5) 
0.2* 
(0.2) 
0.7# 
(0.2) 
0.0 0.6 0.0 1.1 1.0 0.9 0.0 0.2 
butyarate 9.0 
(1.8) 
14.9 
(3.1) 
8.7 
(4.1) 
13.2 
(2.6) 
2.1 16.5 14.9 18.6 1.4 10.3 16.6 7.4 
iso-
valerate 
1.7 
(0.2) 
3.0** 
(0.7) 
0.3* 
(0.1) 
1.2 
(0.4) 
0.4 0.9 0.3 2.1 0.5 1.2 0.0 0.5 
valerate  1.5 
(0.3) 
1.9** 
(0.6) 
0.1* 
(0.1) 
0.6 
(0.4) 
0.2 1.9 0.0 0.3 0.0 0.4 0.0 0.0 
total SCFA 
+BCFA 
45.3† 
(8.2) 
93.4 
(17.4) 
50.8 
(25.1) 
94.2# 
(13.4) 
22.6 130.6 121.8 93.8 9.0 85.7 49.8 66.8 
† p≤0.05 healthy controls versus IBD-remission  * p≤0.05 healthy controls versus CD-before 
# p≤0.05 healthy controls versus CD-after  ** p≤0.05 IBD-remission versus CD-before 
SCFA=short-chain fatty acids    BCFA=branched-chain fatty acids  
before/after=before/after infliximab treatment  
Discussion 
We aimed to investigate the composition and activity of the faecal microbiota in patients with active 
Crohn’s disease, to study the effect of anti-TNF-α monoclonal antibody therapy on these 
microbiotas, and to compare them with faecal parameters in Crohn’s patients in remission and 
healthy controls. 
The first conclusion, found with both the classical plating technique and FISH, was that induction 
of disease remission in CD-active patients by infliximab therapy led to an increase in bacterial 
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counts in the faeces. Secondly, a reduced total number of faecal bacteria correlated with a more 
severe disease activity, but was not inherent to the disease itself since the total bacterial number of 
the IBD-remission patients resembled that of the healthy subjects. Significant compositional 
changes that correlated with the physical condition of all studied subjects were only found with the 
plating technique. The detected increases in the number of bifidobacteria, bacteroides, lactobacilli, 
and sulphite reducing clostridia occurred also in all individual CD-active patients upon infliximab 
infusion. Only lactobacilli were present in lower amounts in IBD patients in remission than in 
healthy controls. The trends detected by FISH, that is higher percentages of both low G+C Gram-
positive bacteria and unidentified bacteria in less severe disease activity, needs further study in 
more detail. In general, molecular approaches provide better insights in the composition of the 
faecal microbiota than the plating technique; media are often not truly specific or are too selective 
for certain bacteria (24). But the number of lactobacilli in faeces are often below the detection limit 
in FISH (<107 CFU/gram; see also Table 6.2), so for this latter group one has to rely on the plating 
technique. Microbial compositions in faeces as well as on the mucosal surface of biopsy specimens 
have been used to study the role of (specific) microorganisms in IBD. The relevance of these 
studies was supported by the findings of the CARD15 gene as the first susceptibility gene for CD 
(33,34). The CARD15 protein is mainly expressed in phagocytic cells. Its encoded protein is able to 
induce NFκB after recognition of intracellular bacterial peptidoglycan (35,36). NFκB is an 
important regulator of genes involved in a pro-inflammatory response (37).  
A study in which IBD tissue was investigated with molecular techniques reported that the mucosal 
surface of IBD patients with active disease contained more bacteria than on those of non-IBD 
controls (38). Others were unable to confirm these findings and reported similar bacterial 
colonization densities on the colonic mucosal surface of IBD patients and controls (39,40). Apart 
from this discrepancy with respect to bacterial counts, discrepant results were also observed for the 
diversity of the microbiota on the colonic mucosal surface in patients with CD. Some reported that 
this diversity was reduced up to 50% in comparison with controls (38,39). One study group found 
that CD tissue samples mainly harboured bacteria belonging to Proteobacteria, the 
Enterobacteriaceae, and the Bacteroides/Prevotella cluster (38), while others found that the 
reduction in diversity of the microbiota on the colonic mucosa in CD was due to loss of normal 
anaerobic bacteria such as Bacteroides species, Eubacterium species, and Lactobacillus species 
(39). In contrast, another group, when comparing tissue samples from the descending colon of 
patients with UC (two inactive, one active) and healthy individuals, found no significant differences 
with respect to the composition of the predominant bacterial community, and that of the 
Lactobacillus group community (40). Investigators, which like us used faeces to detect if the 
microbiota of IBD patients may be different from that of healthy individuals, also reported varying 
results. Both an increase (41) and a decrease (42) in faecal Bacteroides have been reported in 
patients with CD compared to controls. Two study groups showed a reduced score of bifidobacteria 
in these patients compared to controls, and reported an increased number of enterobacteria in 
(active and inactive) CD (42) and Escherichia coli in active CD (43). But the significantly reduced 
Lactobacillus score in patients with CD compared to controls was only found by Giaffer et al. (43). 
Van der Waaij (44) has recently shown that the microbial composition of (solid) faeces was 
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comparable to the microbial composition of the luminal contents in the proximal colon, as well as 
that of the colonic mucosa. But comparing the results of our study with results from IBD tissue 
investigations requires caution. Zoetendal et al. (40) used a 16S rRNA approach to demonstrate that 
the predominant mucosa-associated bacterial community was significantly different from the faecal 
community. Furthermore, Marteau et al., (45) found that the human caecal microbiota differs 
quantitatively and qualitatively from the faecal microbiota. In conclusion, at this moment results 
with respect to bacterial counts and the diversity of the microbiota are still sometimes conflicting 
despite the use of accurate modern molecular techniques. Furthermore, no real consensus exists 
which material (faeces, colonic contents, biopsy specimens) has to be studied and how to compare 
the results when different techniques (plating, DGGE, FISH or dot blot) have been used. To 
overcome these problems, the intestinal microbiota in IBD should be further studied, using different 
techniques, materials, and patients simultaneously. 
A shift in favor of D-lactate and an increase in faecal dry matter was seen for every individual CD-
active patient as a result of a first, single infliximab infusion. These two parameters overall 
correlated with the physical condition of all studied subjects; the less severe disease activity, the 
lower the L-lactate excretion compared to the D-lactate excretion and the higher the faecal dry 
matter. Furthermore, given the significant differences concerning these two parameters between the 
healthy individuals and the IBD patients in remission, lower faecal dry matter and a higher L:D 
lactate ratio seem inherent to IBD. These two parameters can possibly be used as faecal disease 
activity marker.  
The shift in favor of D-lactate is compatible with reduced host L-lactate production and/or increased 
bacterial D-lactate formation (46). The increase in total number of faecal bacteria when disease 
activity became less severe could correspond to an increased bacterial lactate formation. 
Concerning faecal dry matter we may also conclude that, given the significant difference between 
the IBD-remission group and the healthy controls, patients suffering from quiescent IBD still show 
a fast transit time and/or reduced net fluid absorption, resulting in a high water content of their 
faeces. Furthermore, the differences seen in total number of bacterial counts between the groups 
with different disease activities was not the result of differences in faecal dry matter. When 
expressed as CFU/gram dry matter total bacterial counts still were significantly higher in healthy 
controls compared to CD-active patients before infliximab infusion (plating: p=0.02; FISH: 
p=0.04). 
Faecal SCFA and BCFA excretion did not correlate with anti-TNF-α treatment or with health status 
of the tested (sub)groups. It is remarkable that for the metabolites most abundantly present in faeces 
(i.e. acetate, propionate, and butyrate) excretions by the healthy individuals resembled that of the 
CD-active patients before infliximab treatment, and excretions by the IBD patients in remission 
were similar to that by the CD-active patients after the treatment. The difficulty with faecal 
metabolites is that elevated concentrations may reflect impaired absorption and/or utilization as 
well as increased production. Which of these two aspects applies, or to what extent each of these 
aspects contributes to increased levels of microbial metabolites in these faecal samples remains to 
be studied. The phenomenon seen for excretions of acetate, propionate, butyrate, and also total 
SCFA in faeces can be explained as follows. A higher bacterial colonization density may be 
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associated with a higher total microbial activity. Excretion of these microbial metabolites in faeces 
is the result of microbial activity minus mucosal absorption and/or utilization. Therefore, we may 
conclude that a higher faecal excretion of microbial metabolites then that found for healthy 
individuals, combined with an equal total faecal number of bacteria to that of healthy individuals 
mean that the mucosal absorption and/or utilization is impaired. This seems to be the case for the 
IBD remission group, as well as for the CD-active patients after infliximab treatment (based on 
faecal number of bacteria determined by FISH and acetate, propionate, butyrate and total SCFA 
excretion). Furthermore, faecal excretions of microbial metabolites equal to that found for healthy 
individuals, combined with a lower total faecal number of bacteria to that of healthy individuals can 
also mean that the mucosal absorption and/or utilization is impaired. This seems to be the case for 
the CD-active patients before infliximab treatment. To confirm these conclusions, more (infliximab 
treated) patients should be investigated. Concentrations of SCFA and lactate in faeces of IBD 
patients have been determined before. The reported results are conflicting, pointing out the 
difficulty of using faeces. Children with UC and ileocolonic CD had a significant decrease in the 
faecal concentration of acetate, a significant increase in butyrate, while no changes in fecal lactate 
were seen compared with age-matched controls (47). Especially the faecal samples of inactive- or 
mild-UC children showed increased butyrate levels, whereas the faecal samples of moderate- and 
severe-UC children were mainly responsible for the decreased total SCFA and acetate levels. Others 
however found increased lactate (mainly L-lactate) levels in adult ulcerative colitis patients with 
either pancolitis or proctitis compared with quiescent disease. In this study, lactate concentrations 
correlated with the disease activity index of Truelove. Lactate was also increased in Crohn's colitis 
compared with quiescent CD, but lactate did not correlate with a disease activity index. This study 
did not find a correlation of SCFA (including butyrate) with inflammatory activity or localization in 
either ulcerative colitis or Crohn’s disease (48). Our results correspond partly with these latter 
observations.  
In conclusion, in this pilot-study active IBD is associated with a significant reduced total number of 
faecal bacteria and a significant lower faecal dry matter than found in healthy controls. Induction of 
disease remission leads to an increase of both parameters. These changes are associated with a 
decrease in the L- versus D-lactate ratio. These three parameters can possibly be used as clinical 
disease activity markers. For this, larger studies need to be undertaken. 
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The role of the microbiota in IBD 
Intestinal bacteria drive the inflammatory process in IBD. Loss of tolerance to bacteria indigenous 
to the large intestine, the role of bacteria in disease development in animal models of IBD, 
responses of IBD patients to antimicrobial therapy, and infiltration of inflammatory bacterial 
products across the intestinal mucosal barrier, altogether reveal the possible role of microbes in 
IBD. Some suggest that specific microorganisms play a role in the induction of inflammation, while 
others think that metabolites derived from the microbiota, without regard to species, can be 
mediators of injury and inflammation. Unfortunately, there is a lack of solid data to substantiate this 
latter hypothesis. This is primarily due to the fact that the study of microbial metabolic activity is 
difficult, among others for reasons of sampling and difficulties in mimicking physiological 
circumstances ex vivo. Our TIM-2 system overcomes a lot of these difficulties and is therefore 
relevant for the study of microbial metabolic activities (1-4). In this thesis the effect of the 
microbiota on the onset and exacerbation of IBD was investigated, with a focus on microbial 
activity.  
 
In the current chapter the results from the preceding chapters are discussed. The discussion focuses 
on the role of microbial metabolites in IBD and is followed by a summary of the main conclusions 
derived from the research described in this thesis. 
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Composition of the microbiota 
The first aspect in the study of the role of the microbiota in IBD is determining the composition of 
faecal microbiota with regard to bacterial counts and species. In chapter 6 we investigated the 
faecal microbial composition of healthy adults and IBD patients both in remission and during 
disease exacerbation using classical plating and FISH. The patients with active disease were studied 
both before and after treatment with a biological therapy (anti-TNF-α antibodies; see also below).  
With both plating and FISH techniques, we found an overall higher number of bacteria in faeces of 
Crohn’s patients after treatment than before. These numbers were also compared with outcomes in 
faecal samples of IBD patients in remission and healthy controls. From these comparisons it may be 
concluded that disease remission correlates with an increase in total faecal bacterial counts, which 
approach levels observed in healthy controls. 
Metabolic activity of the microbiota 
Microbiota originating from healthy individuals versus out-of-balance microbiota 
Before investigating the role of microbial metabolites in IBD, we first aimed to understand which 
metabolites are produced during the normal colonic fermentation process by a microbiota 
originating from healthy human individuals and which metabolites are produced when this 
microbiota is out-of-balance. In chapter 2 TNO's dynamic in vitro model of the large intestine 
(TIM-2) was used to investigate the production of microbial metabolites by a standardized 
microbiota, representative for the healthy human proximal colon. The emphasis was on toxic 
metabolites, such as ammonium, phenols and indoles, and BCFA. Clostridium difficile was 
introduced into TIM-2 to study the potential for toxic metabolite production by a microbiota that is 
out-of-balance. Furthermore, the effect of inulins with different degree of polymerisation (ranging 
from 3 to 25) on the saccharolytic- and proteolytic activity of both types of colonic microbiota was 
investigated. Inulin is regarded a prebiotic; it increases the number and/or activity of specific 
microorganisms in the gastrointestinal tract presumed to be health promoting (5). 
The addition of inulin to the standardized, healthy microbiota suppressed the formation of BCFA, 
ammonium, and phenolic compounds while at the same time SCFA and lactate production was 
stimulated. Since BCFA, ammonium, and phenolic compounds are products typical of breakdown 
and fermentation of proteins it can be concluded that inulins inhibit the proteolytic activity of the 
colonic microbiota and stimulate the saccharolytic activity, as indicated by the increased SCFA and 
lactate production. The introduction of C. difficile caused an expected stimulation of the production 
of the protein fermentative metabolites. This negative effect of C. difficile was almost completely 
prevented by the addition of inulins, irrespective of the chain length.  
In conclusion, the results of the study described in chapter 2 indicate a potential for inulins to shift 
the metabolic activity of the human colonic microbiota towards the production of less potentially 
toxic metabolites, both under normal conditions and under conditions with a microbiota that is out-
of-balance. The introduction of only a small number of C. difficile bacteria (only about 1% or less 
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of the total bacterial population was added) caused a major shift in the overall metabolism of the 
colonic microbiota towards proteolysis.  
Metabolic activity of the microbiota of IBD patients 
Changes in the microbiota may also have an effect on metabolite production, which in theory may 
lead to increased levels of toxic metabolites in patients with active inflammatory bowel disease. It is 
therefore of great interest to determine whether individuals with IBD show evidence of an altered 
metabolic function of the microbiota in the large intestine and whether this relates to the onset or 
progression of the disease. Dietary interventions in these patients, with for instance prebiotics, may 
have the same effect on the metabolic activity of the microbiota as that shown for healthy 
individuals in chapter 2. Some published data suggest that the metabolic activity of the large 
intestinal microbiota of patients suffering from UC and CD is different compared to that of healthy 
individuals. If this difference in activity resembles an out-of-balance situation, resulting in a higher 
level of potentially toxic metabolites, this activity can be a mediator of injury and inflammation.  
In the third chapter we therefore investigated whether the microbiota of IBD patients indeed show 
such an altered metabolic activity in the proximal colon in comparison with healthy controls and 
whether this is related to the severity of the disease. For that purpose, TIM-2 was inoculated with 
fresh faeces of 6 healthy individuals and 8 IBD patients. Samples were taken from the model over 
time to analyze metabolites from both saccharolytic- and proteolytic fermentation. We observed 
higher production of SCFA and BCFA, as well as ammonia, in the experiments using faeces of IBD 
patients compared to that of controls. These differences were not observed for the production of 
phenolic compounds and lactate, which varied greatly.  
The higher metabolite production in IBD patients is in agreement with literature data obtained with 
other methods (6-8). The cause of the higher metabolic activity in these patients is unknown. Using 
TIM-2, we showed that damage to the mucosa, resulting in inadequate absorption of these 
metabolites, is not the cause of the increased metabolite concentrations, although it may contribute 
to a higher excretion of these metabolites in faeces of IBD patients (see chapter 6). The higher 
production of (potentially toxic) metabolites in IBD patients may play a role in the onset or 
chronicity of IBD.  
The results described in chapter 3 may have been influenced by a number of potential confounders. 
During the experiments in TIM-2, the pH was set at 5.8. This is the pH in the proximal colon of 
healthy individuals (9). No extensive research is done in IBD patients concerning the pH in (this 
part of) the colon. Another debatable point is the digestion of food in the upper gastrointestinal tract 
in these individuals; if this function of the gastrointestinal tract in IBD patients also deviates from 
healthy individuals, the IBD microbiota in TIM-2 are fed other substrates than in vivo, which will 
result in different metabolite profiles. Without extensive knowledge of the environmental 
circumstances in the proximal colon of IBD patients, the results described in chapter 3 should be 
interpreted with caution. 
The proteolytic activity of the gut microbiota can increase remarkably, in the distal colon compared 
to the proximal colon even by a factor of 5 (10-12). Therefore, fermentation in the transverse and 
descending parts of the colon will give more insight into the total colonic health status. An in vitro 
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system simulating this distal part, with physiological parameters, such as lower water content and a 
higher pH, is in development at our institute and will be used in the future to study the metabolic 
activity of microbiotas obtained from healthy persons and IBD patients under even more relevant 
physiological conditions. 
Role of nutrition in IBD 
The microbial activity in the colon is in part defined by the components of the food that reach this 
part of the digestive tract. The results of both the first (chapter 2) and the second (chapter 3) study 
showed that feeding microbiotas of healthy humans approximately 5 g of protein per day, which is 
about one third of the estimated amount that becomes available in the proximal colon in vivo 
(13,14), results in the production of detectable amounts of potentially toxic or harmful metabolites. 
Since the model mimics the environmental conditions of the healthy proximal colon, this indicates 
that even in a region of the gut where protein fermentation is of minor importance these substances can 
still be produced.  
To control disease activity, some dietary compounds, such as proteins, can be removed from the 
diet of IBD patients whereas others, such as prebiotics, can be added to the normal diet. In chapter 
2 we showed that inulin indeed acted as a prebiotic; it reduced the production of proteolytic 
fermentation products, both under normal conditions and under conditions with a microbiota that is 
out-of-balance. We observed higher production of SCFA and BCFA, as well as ammonia, in the 
experiments using faeces of IBD patients compared to that of controls (chapter 3); whether the 
addition of inulins to these microbiotas of IBD patients also results in suppression of the formation of 
BCFA and ammonia, and in even a further increase in SCFA production needs to be studied. Also more 
detailed studies are needed to clearly establish the relevance of even small amounts of protein in 
IBD.  
Defense 
Intestinal epithelial cells (IEC) that line the gastrointestinal mucosa can be regarded as the most 
outer defence barrier preventing microorganisms and endotoxins from reaching systemic organs and 
tissues (15-18). The relation between IEC, luminal microbiota, and IBD appears evident. IEC play 
an important role in the interaction between luminal content and the host’s immune system 
(16,17,19), while a role for the microbiota in triggering the inflammatory process has been proposed 
(20-22). Both luminal microorganisms and their metabolites can possibly influence the metabolic 
integrity of the IEC, resulting in presentation of these antigens to the mucosal immune system (23-
25). 
The ability of the colonic mucosa to detoxify metabolites derived from proteolytic fermentation 
seems to be impaired in UC (11), causing the colonic tissue of patients to be more susceptible to the 
toxicity of these compounds than colonic tissue of healthy individuals. If so, the microbial activity 
in the colon of IBD patients can certainly serve as an indicator of disease severity. However, 
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without ex vivo or in vivo tests on the toxicity of these compounds, it cannot be concluded which 
metabolites (and at which concentrations) cause injury to the epithelial barrier of IBD patients.  
Studying defense by using cell cultures 
We hypothesized that the increase in production of microbial metabolites (chapter 3) contributes to 
IEC injury and/or loss of the integrity of the barrier function in IBD. Enhanced presentation of these 
microbial metabolites to the mucosal immune system may then play a role in the maintenance of 
IBD activity. In chapter 4 we aimed to investigate which metabolites, and at which concentrations, 
cause injury to epithelial cells and thereby might stimulate unwanted immune reactions. This was 
studied by co-culturing enterocyte-like Caco-2 cells with macrophages in separate compartments of 
a TranswellTM system. In addition, the direct effect of butyrate (C4), iso-valerate (i-C5), and 
ammonium (NH4+) on Caco-2 cells and macrophages separately was tested. Barrier function of the 
Caco-2 monolayer (mono-culture and co-culture) was determined by measuring transepithelial 
electrical resistance and basolateral recoveries of the microbial metabolite. Also the contribution of 
microbial metabolites to the chronic inflammatory process by stimulating induction of pro- and 
anti-inflammatoy cytokines (TNF-α and IL-10, respectively) by Caco-2 cells and macrophages was 
investigated. The following concentrations were tested: 5-100 mM (C4), 4-100 mM (i-C5), and 2-
40 mM (NH4+) . 
Information about luminal concentrations of C4, i-C5 and NH4+ in vivo is scarce. Two studies give 
some more information of what can be produced in vivo. Cummings et al. (26) and MacFarlane et 
al. (27) measured SCFA, BCFA, and ammonium in colonic luminal contents of sudden-death 
individuals. The intraluminal concentrations of C4, i-C5, and NH4+ in the proximal colon were 38, 
2, and 20 mmol/kg wet weight contents, respectively (27). The observed maximum intraluminal 
metabolite concentrations produced by IBD microbiotas in an in vitro model were approximately 30 
mM for C4, 5 mM for i-C5 and 65 mM for ammonium (28). However, both these in vivo and in 
vitro concentrations were totally dependent on the moment of sampling; it cannot be concluded that 
intraluminal concentrations of C4, i-C5 and NH4+ in healthy persons or in IBD patients do not reach 
higher levels, for instance simply because of diet. In case of an impaired epithelial barrier, such as 
in patients with an inflamed ulcerated colon, colonic macrophages can be exposed to luminal 
concentrations of microbial metabolites.  
Our in vitro exposure experiments in chapter 4 showed that the barrier function of IEC is not easily 
disturbed by microbial metabolites. Exposure to ammonia (10-40 mM), or to high concentrations of 
C4 or i-C5 (100 mM) lowered TEER values of Caco-2 mono-cultures, but the absolute TEER levels 
remained higher than 500 Ω*cm2, a level which is compatible with an intact barrier function (29). 
As a result, basolateral recovery of metabolites was in the same order of magnitude in all 
experiments, regardless of type of experiment (mono- or co-culture), metabolite, or concentration of 
metabolite tested. Basolateral recoveries ranged from 6.2% to 15.2%. However, it cannot be 
concluded that intraluminal concentrations of C4, i-C5 and NH4+ in IBD patients do not lead to 
increased permeability of the barrier function in vivo because we do not know how sensitive 
intestinal epithelial cells of IBD patients are. The Caco-2 cells did not secrete TNF-α or IL-10. 
Concentrations of butyrate and iso-valerate as high as those produced by IBD patients stimulated 
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the secretion of TNF-α and suppressed the secretion of IL-10 by macrophages that are not protected 
by an epithelial barrier. In contrast, ammonium concentrations close to those produced by 
microbiotas of IBD patients suppressed the release of both cytokines when the barrier function is 
impaired.  
Due to the (intact) barrier function of the Caco-2 cells, the TNF-α and IL-10 secretion levels in the 
co-culture experiments reflect the effect of exposure of macrophages to approximately 10% of 
concentrations of initial amounts of metabolites added to the luminal side in the TranswellTM. In 
this co-culture set-up, ammonium no longer had an inhibitory effect on secretion of TNF-α and IL-
10 by macrophages (levels of both cytokines were as high as with LPS). The effect of the other 
metabolites remained pro-inflammatory, even when the macrophages were protected by an 
epithelial barrier. The concentrations of C4 and i-C5 tested in the co-culture experiments are higher 
than the concentrations found in vivo (sudden death individuals) and in vitro (IBD faeces in in vitro 
model). However, butyrate is likely to reach concentrations of 50 or 100 mM, for instance upon 
consumption of prebiotics.  
Both the supposed positive effect of C4 and the supposed negative effect of NH4+ are not confirmed 
by the present experiments. Our results are contrasting with the limited data available concerning 
butyrate and the production of cytokines: studies with whole-blood models and isolated 
mononuclear cells showed that butyrate (to a maximum of 2 mM) reduced LPS induced TNF-α 
and/or IL-10 production (30-32). A complex mixture of microbial metabolites, obtained from 
TNO’s in vitro model of the large intestine, reduced TNF-α and INF-γ, while inducing IL-10 (van 
Nuenen et al., manuscript in preparation). This might indicate that metabolites in combinations 
might have opposing or synergistic effects. We are currently studying this in more detail, including 
the effect of the cytokines on the barrier function. 
In conclusion, the results of the study described in chapter 4 indicate that the barrier function of 
intestinal epithelial cells in vitro is not disturbed by the microbial metabolites when tested 
separately, but these metabolites are able to modulate the secretion of both TNF-α and IL-10 by 
macrophages underlying the epithelium. The enhanced production of C4 and i-C5 by the 
microbiotas observed in chapter 3 may thus play a role in the maintenance of IBD activity. 
Biological therapy for IBD 
Novel therapeutic approaches for the treatment of IBD often use biologic agents that 
mechanistically target individual inflammatory pathways. Some biological agents have already been 
proven to be effective for CD and UC (33-35), others are still under investigation (36-39). Besides 
immunological strategies, also the targeting of therapeutics to improve topical delivery is a strategy 
for IBD that can be realized using a biological approach (38,40). In microbiological strategies, 
microorganisms are used to modify the gut microbiota and they are called probiotics. More recently 
genetically engineered bacteria have been constructed that can function as a probiotic, such as 
lactococci that secrete immunosuppressive IL-10 (41). 
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Interleukin-10 secreting lactococci 
Irrespective of whether or not the primary disorder in IBD is immunological in nature, a good 
therapeutic approach in CD is the inhibition of TH-1 polarization of the immune system by using the 
immunomodulatory recombinant human IL-10. This cytokine controls and suppresses inflammation 
essentially by down regulating pro-inflammatory cytokine production. A number of studies with 
animal models of IBD have shown the efficacy of IL-10 for the regulation of mucosal 
inflammation. A new development in IBD-therapeutics is the targeted delivery of IL-10 to the site 
of inflammation by means of in situ synthesis using a recombinant L. lactis. For this therapy to be 
efficacious, an important criterion is the survival of the L. lactis strain in the upper gastrointestinal 
tract of the host (42,43). 
In chapter 5 we aimed to determine whether targeted delivery of hIL-10 producing L. lactis could 
be obtained by incorporating the strain in an enteric-coated capsule formulation. Survival and 
metabolic activity of the recombinant L. lactis was studied in TIM-1, simulating the successive 
dynamic processes in the stomach and the small intestine, as stationary-phase grown cells or after 
incorporation in two types of enteric-coated formulation (Eudragit® L30D-55, disintegrating at a pH 
of 6.0 and higher; and Eudragit® FS 30 D, disintegrating at a pH equal to or higher than 7.2). Only 
0.04% of the oral intake of viable cells was recovered for the lactococci taken as stationay-phase 
grown cells. Incoporating L. lactis in Eudragit® L30D-55 coated capsules increased the viable cells 
to 0.28% and Eudragit® FS 30 D coated capsules improved this further to 1.21%. The capacity of 
the cells to secrete hIL-10 was validated in vivo in pigs (44), but was not observed in our in vitro 
systems. The reason for this was that, contrary to the pig experiment, the absolute amount of viable 
bacteria that would have been able to produce hIL-10 in vitro was to low to produce hIL-10 
concentrations that are above the detection limit of an ELISA assay. Nevertheless, the study clearly 
indicated that both types of capsules are effective in protecting lactococci during passage through 
the stomach and (parts of) the small intestine. Depending of the desired site of action of the cells, 
the proper capsule can be chosen. If the site of action should be the jejunum, a Eudragit® L30D-55 
coated capsule is the preferred choice of dosage form; if the site of action is the ileum or proximal 
colon, a Eudragit® FS 30 D coated capsule should be chosen. 
From chapter 5 we can conclude that, even though survival of L. lactis is low when expressed in 
percentages, total viable cell numbers of L. lactis at the end of the small intestine reach 2.4 * 108–
1.2 * 109. In our in vitro model we have shown proof-of-principle for the delivery of these cells in 
the gastrointestinal tract. Enteric-coated capsules for ileal delivery of hIL-10 producing L. lactis can 
thus be a potential therapy for CD. Combining these results with the outcome of a preclinical study 
in which the same two formulations with hIL-10 producing L. lactis has been administered to 10 
patients suffering from CD (Amsterdam Medical Centre, The Netherlands) will provide valuable 
insight into safety, biological containment and clinical effectiveness of this novel medical strategy. 
Monoclonal antibodies against TNF-α 
Another therapy currently in practice in IBD is the use of anti-TNF-α monoclonal antibodies. These 
antibodies block TNF-α, a powerful immune stimulator. A single intravenous dose of this biological 
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therapy results in reduced CD activity scores and increased remission. In chapter 6 we aimed to 
investigate the composition and activity of the faecal microbiota in patients with active CD, to study 
the effect of anti-TNF-α monoclonal antibody (infliximab) therapy on these microbiotas, and to 
compare them with faecal parameters in Crohn’s patients in remission and healthy controls. 
Microbial composition was determined using the classical plating technique and FISH, and the 
potential disease activity markers determined in the faecal samples were dry matter, pH, SCFA, 
BCFA, and lactate. 
The first conclusion, found with both the classical plating technique and FISH, was that induction 
of disease remission in CD-active patients by infliximab therapy led to an increase in bacterial 
counts in the faeces. Secondly, a reduced total number of faecal bacteria correlated with a more 
severe disease activity, but was not inherent to the disease itself since the total bacterial number of 
the IBD-remission patients resembled that of the healthy subjects. Increases in the number of 
bifidobacteria, bacteroides, lactobacilli, and sulphite reducing clostridia correlated with the physical 
condition of all studied subjects and occurred also in all individual CD-active patients upon 
infliximab infusion. Only lactobacilli were present in lower amounts in IBD patients in remission 
than in healthy controls. The trends detected by FISH, that is the lower severity of disease, the 
higher the percentages of both low G+C Gram-positive bacteria and unidentified bacteria, can be 
interesting to study in more detail. Microbial compositions in faeces as well as on the mucosal 
surface of biopsy specimens have been used to study the role of (specific) microorganisms in IBD. 
In conclusion, at this moment results with respect to bacterial counts and the diversity of the 
microbiota are still sometimes conflicting despite the use of accurate modern molecular techniques. 
Furthermore, no real consensus exists which material (faeces, colonic contents, biopsy specimens) 
has to be studied and how to compare the results when different techniques (plating, DGGE, FISH 
or dot blot) have been used (45-52). To overcome these problems, the intestinal microbiota in IBD 
should be further studied, using different techniques, materials, and patients simultaneously. 
Concerning the potential disease activity markers determined in the faecal samples, a shift in favor 
of D-lactate and an increase in faecal dry matter was seen for every individual CD-active patient as 
a result of a first, single infliximab infusion. These two parameters overall correlated with the 
physical condition of all studied subjects; the less severe disease activity, the lower the L-lactate 
excretion compared to the D-lactate excretion and the higher the faecal dry matter. Furthermore, 
given the significant differences concerning these two parameters between the healthy individuals 
and the IBD patients in remission, lower faecal dry matter and a higher L:D lactate ratio seem 
inherent to IBD.  
In conclusion, in the pilot-study described in chapter 6 active IBD is associated with a significant 
reduced total number of faecal bacteria and a significant lower faecal dry matter than found in 
healthy controls. Induction of disease remission leads to an increase of both parameters. These 
changes are associated with a decrease in the L- versus D-lactate ratio. These three parameters can 
possibly be used as clinical disease activity markers. For this larger studies need to be undertaken 
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Main conclusions 
• When studying the effect of the microbiota on the onset and exacerbation of IBD both the 
composition of the intestinal microbiota as well as the metabolites derived from this 
microbiota should be analysed. 
• Results concerning the microbial composition of IBD patients are still conflicting although 
nowadays modern molecular techniques are used. No consensus exists in which material 
(faeces, colonic contents, biopsy specimens) has to be studied and how to compare the 
results when different techniques (plating, DGGE, FISH or dot blot) have been used. To 
overcome these problems, the intestinal microbiota in IBD should be further studied, using 
different techniques, materials, and patients simultaneously. 
• Active inflammatory bowel disease is associated with a significant reduced total number of 
faecal bacteria and a significant lower faecal dry matter than found in healthy controls. 
Induction of disease remission leads to an increase of both parameters. These changes are 
associated with a decrease in the L- versus D-lactate ratio. These three parameters can 
possibly be used as clinical disease activity markers. For this larger studies need to be 
undertaken. 
• The study of microbial metabolic activity is difficult, among others for reasons of sampling 
and difficulty mimicking physiological circumstances ex vivo. TNO’s in vitro system of the 
proximal colon turned out to be relevant for studying microbial metabolic activity although 
one should keep in mind the disadvantages of using such a system. 
• Inulins inhibit the proteolytic activity of the colonic microbiota and stimulate the 
saccharolytic activity, both under normal conditions and under conditions with a microbiota 
that is out-of-balance. 
• The introduction of only a small number of C. difficile bacteria (≤ 1 % of the total bacterial 
population was added) caused a major shift in the overall metabolism of the colonic 
microbiota towards proteolysis.  
• The production of (potentially toxic) metabolites may play a role in the onset or chronicity 
of inflammatory bowel disease, because they were produced in higher amounts by 
microbiotas from these patients than by microbiotas from healthy individuals. 
• The barrier function of intestinal epithelial cells in vitro is not disturbed by the microbial 
metabolites butyrate (≤ 100 mM), iso-valerate (≤ 100 mM), or ammonium (≤ 40 mM). But it 
cannot be concluded that intraluminal concentrations of butyrate, iso-valerate and 
ammonium in IBD patients do not lead to increased permeability of the barrier function in 
vivo because we do not know how sensitive intestinal epithelial cells of IBD patients are.  
• In case of an impaired epithelial barrier, such as in patients with an inflamed ulcerated 
colon, colonic macrophages can be exposed to luminal concentrations of microbial 
metabolites. Physiological concentrations of butyrate and iso-valerate both stimulated the 
secretion of TNF-α and suppressed the secretion of IL-10 by macrophages that are not 
protected by an epithelial barrier. In contrast, ammonium concentrations close to those 
produced by microbiotas of IBD patients suppressed the release of both cytokines when the 
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barrier function is impaired. The enhanced production of butyrate and iso-valerate by the 
microbiotas of IBD patients may thus play a role in the maintenance of IBD activity. 
• More detailed studies are needed to establish the relevance of a lower proteolytic activity of 
the colonic microbiota (inulins), a higher saccharolytic activity (inulins, microbial activity of 
IBD patients in remission), or a higher proteolytic activity (C. difficile, microbial activity of 
IBD patients in remission) on the gastrointestinal health status. 
• Damage to the mucosa, resulting in inadequate absorption of microbial metabolites, 
contributes to a higher excretion of these metabolites in faeces of IBD patients. We did not 
only show a higher faecal excretion of microbial metabolites for some IBD patients 
compared to healthy individuals, but also a higher production of metabolites in IBD patients. 
To what extent each of these aspects contributes to the onset or chronicity of IBD remains to 
be studied.  
• The cause of the higher metabolic activity in IBD patients is unknown. The role of the total 
microbial number and the environmental circumstances (pH, amount of food) in the 
proximal, transverse, and distal colon of IBD patients should all be investigated to determine 
the effects on the level of microbial activity. 
• Novel therapeutic approaches for the treatment of IBD can be investigated using the TNO in 
vitro models of the upper gastrointestinal tract and the proximal colon. Experiments in   
TIM-1 showed that the hIL-10 producing L. lactis can indeeed be a potential therapy for CD 
because the enteric-coated capsules protected the lactococci and delivered them to the ileum. 
The effect of for instance increased TNF-α concentrations at the luminal site of the colon, or 
a decrease of this cytokine as a result of infliximab treatment on metabolic activity and/or 
microbial compositions should be studied in TIM-2 to make up the results out of chapter 6. 
Especially when investigating drugs in the treatment of IBD wherein the microbial activity 
is involved, as is the case for sulfasalazine, a TIM-2 system simulating the dynamics of the 
colon of an IBD patient would be an excellent screening tool.  
• Once the role of the metabolic activity of the microbiota will become clearer, dietary 
interventions of IBD may become feasible by the possibility to modulate this metabolic 
activity. The provided biomarkers can possibly be used in prevention and treatment of the 
disease in humans. 
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